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ABSTRACT OF DISSERTATION

THE ROLE OF PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1
IN RECEPTOR TRAFFICKING AND DISEASE
The progesterone receptor membrane component 1 (PGRMC1) is a
multifunctional protein with a heme-binding domain that promotes cellular
signaling via receptor trafficking, and is essential for some elements of tumor
growth and metastasis. PGRMC1 is upregulated in breast, colon, lung and
thyroid tumors. We expanded the analysis of PGRMC1 in the clinical setting, and
report the first analysis of PGRMC1 in human oral cavity and ovarian tumors and
found PGRMC1 to correlate with lung and ovarian cancer patient survival.
Furthermore, we discovered a specific role for PGRMC1 in cancer stem cell
viability. PGRMC1 directly associates with the epidermal growth factor (EGFR) in
cancer cells, and we reviewed multiple signaling-associated pathways that are
important in trafficking wild-type and mutant EGFR. To better understand the
potential of PGRMC1 in receptor tyrosine kinase trafficking, we extended our
research to the insulin receptor (IR). Changes in insulin signaling have been
linked to multiple diseases, because IR plays a key role in glucose metabolism,
cellular survival and proliferation. We found PGRMC1 to co-precipitate with IR in
cancer cells and in an adipose model system. PGRMC1 increased IR plasma
membrane levels in multiple cancer cell lines, and was also found to increase
plasma membrane levels of two glucose transporters. Treatment with a PGRMC1
ligand significantly increased IR levels in human adipocytes. Moreover, we
demonstrate that both insulin binding and glucose uptake are dependent on
PGRMC1.
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CHAPTER I: INTRODUCTION
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Progesterone receptor membrane component 1 (PGRMC1) is a highly
conserved ligand binding protein that is widely distributed throughout eukaryotic
organisms (1). PGRMC1 belongs to the membrane-associated progesterone
receptor (MAPR) family, which includes PGRMC1, PGRMC2, neudesin (NENF)
and neuferricin (CYB5D2) (2). This family of proteins is involved in
multifunctional physiological properties related to cholesterol and steroid
biosynthesis, drug metabolism and response, autophagy, apoptosis, cell cycle
regulation, cell migration, tumorigenesis and cancer progression, receptor
trafficking and neural functions (2).

1.1 PGRMC1: Discovery and Nomenclature
PGRMC1 has been identified independently by various groups in multiple
biological contexts. PGRMC1 was initially discovered and purified in 1996 by
Meyer and colleagues, as a high-affinity progesterone-binding site derived from
porcine liver membranes (3, 4). In the same year, the gene was isolated from
the livers of dioxin treated rats, and named 25-Dx (5). In 2001, PGRMC1 was
identified as an immunologically defined antigen and named inner zone antigen
(IZA) after a monoclonal antibody specific for rat adrenocortical cells (6). The
cDNA encoding IZA was later found to be identical to that encoding the
previously reported putative membrane-associated progesterone receptor (MPR)
and 25-Dx (7).
In 2003, Craven and colleagues at the University of North Carolina
discovered and cloned the Saccharomyces cerevisiae yeast member of the
2

MAPR family, which they named Dap1 (Damage-associated response protein),
and were the first to link the MAPR family member to sterol regulation and
damage response (8). In Caenorhabditis elegans, the Dap1 homologue, termed
VEM-1, was found to be involved in axon guidance in the developing roundworm
(9).
The human PGRMC1 homologue was first cloned in 1998 and named
human progesterone receptor 6.6 (Hpr6.6) (10). In the same paper, they
identified another related human protein of a separate gene (Dg6) that
corresponds to the present PGRMC2 nomenclature (10). The first published
utilization of “PGRMC1” was reported in 2005 (11), as hmPR/PGRMC1, and later
as PGRMC1 in 2006 (12). The current nomenclature approved by the HUGO
Gene Nomenclature Committee is PGRMC1 (1).

1.2 PGRMC1: Structure and localization
PGRMC1 and the MAPR family proteins share a similar non-covalent
heme-binding domain that is similar to cytochrome b5 (1, 13) . The PGRMC1
protein consists of 195 amino acids and contains a short luminal peptide, a single
N-terminal transmembrane segment and C-terminal cytochrome b5 like domain
(13, 14). RT-PCR experiments detect a single transcript corresponding to a
protein ~25kDa, however the protein may exist in different states of
phosphorylation resulting in slight changes in the apparent molecular weight
(MW) (5). The putative structure of PGRMC1 contains a prominent ligand
binding cleft (Figure 1.1) and contains binding sites for Src homology 2 (SH2)
3

and Src homology 3 (SH3) domain-containing proteins and consensus
phosphorylation sites for tyrosine kinases (1). Additionally, PGRMC1 contains
several YXXϕ motifs (ϕ is a large hydrophobic amino acid) that are also known as
immunoreceptor tyrosine-based activation motifs (ITAMS) (15). These motifs are
predominantly involved in cellular protein trafficking and functions include:
targeting membrane proteins to membrane compartments, internalization of
receptors after ligand-binding, and interacting with vesicle coat protein adaptor
protein complexes (1, 15).
In 2006, Craven and colleagues at the University of Kentucky were the
first to demonstrate heme binding directly to PGRMC1, and that a mutation in the
heme-1 domain at the Asp120 residue (D120G, Figure 1.1A) blocks hemebinding activity (16). Heme is composed of ferrous iron and protoporphyrin IX
and is a cofactor in numerous reactions associated with energy production and
metabolism. Indeed, the only known biochemical function of PGRMC1 is heme
binding, and heme binding has been characterized through multiple
spectroscopic and crystallographic studies (16-18). PGRMC1 binds to heme via
a conserved tyrosine residue in a five-coordinate (5C) high-spin (HS)
configuration and has been indicated in heme transport (18, 19). Recent
crystallographic studies have revealed that PGRMC1 can form a stable dimer
through stacking interactions of two protruding heme molecules, and that heme
binding is required for dimer formation (Figure 1.1B-C) (20). The SH3 and SH2
target sequences in PGRMC1 lie adjacent to one another on the opposite
surface to the heme-binding site, potentially providing a site for the recruitment of
4

proteins to the surface of PGRMC1 (15). Based on the structure published in
Nature Communications, it has been suggested that phosphorylation of
PGRMC1 at position Y113 may promote the membrane trafficking function of
PGRMC1 (14). Furthermore, the membrane trafficking activity may switch from a
dimer-dependent “receptor insertion” function to a monomer-dependent “receptor
withdrawal” phenotype in the presence of carbon monoxide (CO) (Figure 1.1C)
(14, 15).
A structure-based screen performed by Yokohama and colleagues
identified four aromatic ligands for the Arabidopsis thaliana PGRMC1 homolog,
AtMAPR2, which are highly conserved with the human PGRMC1 in the heme-1
domain (21, 22). One of the ligands with the highest binding affinity to the heme
binding pocket of PGRMC1 is called AG205 (Figure 1.1D), and was found to bind
PGRMC1 by the Craven group (15, 22, 23). Since then, the small molecule has
been categorized as an inhibitor of PGRMC1, although in certain settings it may
act as agonist (15). Although PGRMC1 does not share any apparent homology
to nuclear or membrane-bound hormone receptors (13, 24), partially purified and
recombinant progesterone have been found to bind PGRMC1 (19, 25).
Recombinant PGRMC1 has only a moderate steroid specificity for progesterone,
and a considerable body of evidence has moved away from PGRMC1 itself
containing progesterone-binding activity (3, 15, 24). It has been proposed that
PGRMC1 either forms a complex with other progesterone-binding proteins or that
it is involved in the regulation of cell surface localization of other proteins that
contain progesterone-binding activity (15, 26).

5

Since the initial discovery of PGRMC1 in rat liver membrane fractions (3),
PGRMC1 has been found to be highly expressed in mammalian liver and kidney
(10). Other tissues with PGRMC1 expression include the steroidogenic and
reproductive tissues, brain, breast, heart, lung, skeletal muscle, pancreas, and
other organs (2). In the cell, PGRMC1 is predominantly localized to endosomes
and the endoplasmic reticulum (27, 28). PGRMC1 also localizes to the actin
cytoskeleton and binds actin (29) and is found in the centromeric region of
chromosomes during oocyte meiosis (30). PGRMC1 is also detected in the
cytoplasm, plasma membrane, and nucleus in some cell types (18, 31).

1.3 Interactions and functional implications

1.3.1 Cytochrome P450 stimulation and cholesterol metabolism
Cytochrome P450 enzymes are heme-dependent monooxygenases that
participate in the detoxification of xenobiotics and metabolism of pharmaceutical
drugs (32). Although the number of P450 enzymes varies among species, the
P450 catalytic cycle is well conserved (32). PGRMC1 has been shown to
interact with several cytochromes P450 (P450s) in unicellular eukaryotes and
multicellular organisms to activate enzymatic activity in sterol biosynthesis and
protect cells from DNA damage (8, 33). The first evidence supporting a role for
PGRMC1 in P450 activation was demonstrated in the PGRMC1 yeast homolog,
Dap1. Dap1 was found to mediate resistance to the azole drugs, Iitraconazole
and fluconazole (inhibitors of sterol synthesis), via activation of Erg11 (human
6

Cyp51) (8, 34) and regulate Erg5 (human Cyp61A1) in the cholesterol synthetic
pathway (34). Dap1 increased the levels of Erg11 (human Cyp51) in a hemedependent manner (35). Yeast cells lacking Dap1 are sensitive to DNA damage
and demonstrate a partial arrest in sterol synthesis (34).
Importantly, Dap1 function is conserved in humans. In 2007, Esplanshade
and colleagues provided evidence for the direct role of the human PGRMC1 in
cytochrome P450 function. In their studies, RNAi-mediated knockdown of human
PGRMC1 reduced the activity of Cyp51 and blocked cholesterol synthesis (32).
Additional co-immunoprecipitation experiments demonstrated stable binding of
PGRMC1 to Cyp51, Cyp3A4, Cyp7A1 and Cyp21A2, indicating a role for
PGRMC1 in cholesterol synthesis, drug and hormone metabolism and bile acid
synthesis (32, 36). PGRMC1 also binds to cytochrome P450 reductase (CPR)
(33).
In addition to binding P450 proteins, PGRMC1 binds to the cholesterol
sensing proteins Insig (insulin-induced gene) and Scap (SREBP cleavage
activating protein) in Cos7 cells (37). Both Scap and Insig form a complex with
the transcription factor SREBP (sterol regulatory element binding protein) and
are involved in a feedback regulation loop. SREBP exists as a precursor form in
the endoplasmic reticulum (ER) until the cholesterol synthesis process is
initiated. Under low cholesterol conditions, the Insig/Scap/SREBP complex
translocates to the Golgi apparatus where SREBP becomes proteolytically
cleaved for entry into the nucleus to induce SRE-driven genes responsible for
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synthesis (1). Scap escorts SREBP to the Golgi apparatus, and Insig can inhibit
the process by binding to Scap (36).
The PGRMC1/Insig/Scap/SREBP complex regulates fatty acid lipogenesis
and cholesterol synthesis, which leads to the downstream stimulation of isoprene
and sterol synthesis (15). Depletion of either PGRMC1 or SCAP protein levels
via pharmacological inhibition (anti-psychotic drugs) was shown to increase
lipogenesis and cholesterogenesis in rat livers, and the effect was reversed with
administration of the steroid antagonist mifepristone (MIF) (38). PGRMC1 also
plays a central role in cholesterol homeostasis, as it has been shown to catalyze
the enhanced ATP-independent incorporation of cholesterol into biological
membranes (15).
This PGRMC1-containing complex has been suggested to modulate
diabetes, autophagy and cancer lipogenesis in a cell-type specific manner (15).
More specifically, it has recently been demonstrated that N-glycoslyation under
the high cytoplasmic glucose conditions of tumor cells is required for tumor
growth, and PGRMC1 may play a role (15).

1.3.2 Damage response and regulation
Cells have developed a variety of pathways for responding to cellular
damage, and the response to damage is critical for cellular survival. Cells
respond to DNA damage and oxidative damage by removing the damage,
delaying cell cycle progression, and activating or repressing gene transcription
(8, 28). Unresolved damage can lead to proliferation, growth arrest, senescence,
8

apoptosis or necrosis. Therefore proteins that regulate responses to cellular
damage in different cell types are of great importance.
Indeed, the PGRMC1 yeast homolog (Dap1), and more specifically the
YPL170W gene, was discovered while conducting a genetic search for novel
yeast genes involved in damage response regulation (8). The DNA damaging
agent methyl methane sulfonate (MMS) is widely used in yeast damage repair
studies, and yeast containing a deletion of the open reading frame of YPL170W
resulted in arrested growth in the presence of MMS (8). Furthermore, a point
mutation within the heme-1 domain in Dap1 also results in damage sensitivity in
the presence of MMS (34). These results support the requirement of Dap1 for
growth and cell cycle progression following cellular damage in the yeast model
system (8, 34).

1.3.3 Chemoresistance
In 1996, the rodent PGRMC1 homolog (25-Dx) was found to be
upregulated in dioxin-induced liver tumors, suggesting its first implication in
cancer (5). In 2003, Difilippantonio and colleagues found PGRMC1 to be
consistently about 2-4 fold more abundant in lung cancer cell lines compared
with healthy lung cell lines, however the finding was not extended to primary
clinical tissues (39). In 2005, the Craven group showed via western blot that
PGRMC1 is significantly elevated in breast cancer tumors compared with
matched nonmalignant tissue and demonstrated limited overexpression in colon
and thyroid tumors (40). In cancer cell lines, PGRMC1 was found to be
9

overexpressed in cell lines originating from breast, thyroid and colon cancers,
and PGRMC1 was localized to the perinuclear region of the cell (40). In the
same year, three isoforms of PGRMC1 were identified in breast cancer tumors,
two of which were differentially more abundant in tumors lacking the estrogen
receptor (ER) (41). In ovarian tumors, PGRMC1 expression increases with
tumor stage (42). PGRMC1 is also secreted by lung cancer cells, as PGRMC1
was significantly elevated in the plasma of lung cancer patients compared to
noncancerous patients (43). Thus, PGRMC1 has been proposed as a potential
biomarker for multiple cancers.
Because the yeast PGRMC1 homolog, Dap1, was found to mediate
damage response to a DNA-alkylating agent, the Craven lab tested the role of
PGRMC1 in resistance to oxidative damage (8). In Hand et al 2003, the human
PGRMC1 protein (fused to an HA epitope) was expressed in the human breast
cancer cell line, MCF-7 (24). PGRMC1 expressing cells became sensitized to
cell death following oxidative damage and PGRMC1 was found to regulate cell
death through a novel oxidative damage response pathway independent of Akt
and IkB (24). These results are consistent with the previous findings in the yeast
homolog, Dap1, and the model in which PGRMC1 regulates cell death (8).
The ability to respond to oxidative stress is a key feature of
carcinogenesis, and one of the primary goals in cancer research is to develop
new ways of inhibiting cancer specific growth. Doxorubicin (Adriamycin) is an
anthracycline antibiotic that is a component of many treatment regimens used for
chemotherapy, often used in the treatment of breast cancer. Doxorubicin acts as
10

a DNA replication inhibitor, specifically blocking the activity of the DNA unwinding
protein, topoisomerase II, to initiate apoptosis or cell cycle arrest (44). Other
chemotherapeutic agents include camptothecin analogs and nitrogen mustards,
which work to inhibit topoisomerase I and alkylate DNA accordingly (40). The
utility of doxorubicin, and many chemotherapies, is limited by its inability to kill all
of the cells within a tumor. Many researchers utilize microarray-based screens to
search for chemotherapy-regulated genes, and in 2005, the Craven lab observed
PGRMC1 to be transcriptionally induced by doxorubicin in the breast cancer cell
line, MDA-MB-231 (44).
To further investigate the role of PGRMC1 in chemotherapy susceptibility,
PGRMC1 was inhibited via RNA inhibition (RNAi) in MDA-MB-231 cells (16).
Treatment with doxorubicin and camptothecin was found to significantly increase
cell death in cells containing the PGRMC1 RNAi. Furthermore, deletion of the
heme-binding domain in PGRMC1 also increased susceptibility of breast cancer
cells to chemotherapeutics (16). These results indicate PGRMC1 inhibition, and
a mutation in the PGRMC1 heme-binding domain, increases the ability of
chemotherapeutic drugs to kill cancer cells (16). Other groups have provided
more evidence in support of this role, as PGRMC1 has been found to attenuate
cisplatin-induced death in both MDA-MB-231 cells and ovarian cells, as well as
death caused by erlotinib and doxorubicin in HCT116 colon cancer cells (15).
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1.3.4 Tumorigenesis and EGFR
Tumor growth and invasion are critical steps in the spread of cancer, and
the proliferation of many cancers are driven by receptor-tyrosine kinases. As
mentioned earlier, PGRMC1 plays a significant role in oxidative damage, and is
induced during dioxin-induced tumorigenesis (5, 28). Oxidative damage
activates transmembrane receptor tyrosine kinases, including the epidermal
growth factor receptor (EGFR), which can lead to subsequent activation of the
serine-threonine kinase Akt (28). PGRMC1 regulates the response to oxidative
damage in the human breast cancer cell line, MCF-7, by sensitizing cells to cell
death (28). Although PGRMC1 hyperactivates the apoptotic protein Akt and
damage response protein IκB in MCF-7cells, cell death was found to be
independent of Akt and IκB (28). Some of the most significant findings in cancer
research involve the identification and targeting of signaling pathways activated
in tumors, and in 2010, the Craven lab found PGRMC1 to promote cancer
progression and associate with EGFR (22, 23).
Because PGRMC1 is upregulated in tumors, the Craven lab sought to
determine the extent to which PGRMC1 regulates tumor growth. Human lung
cancer cells, A549, were infected with lentiviruses containing either a control
plasmid (A549/con) or a plasmid containing a short hairpin RNA targeting the
PGRMC1 gene (A549/RNAi). RNA inhibition successfully established a
PGRMC1-knockdown model system (Figure 1.2A) (22). In in vitro studies,
PGRMC1-knockdown cells failed to proliferate in the absence of exogenous
serum and generate growth in soft agar, supporting a role for PGRMC1 in cell
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proliferation and anchorage-independent growth (22). When cells were injected
into athymic nude mice, only the mice who received control cells (A549/con)
efficiently formed tumors (Figure 1.2B-D), indicating PGRMC1 promotes tumor
growth in vivo. (22). Additionally, the PGRMC1 ligand, AG205, induced cell
death in multiple breast and tumor cell lines (22).
A variety of tumors have EGFR overexpression, and activation of the
EGFR-tyrosine kinase has been linked to increased proliferation, metastasis and
decreased apoptosis (23). There are a growing number of drugs that inhibit
EGFR, including cetuximab, erlotinib, and gefitinib, however patient response
varies (23). After establishing the promotion of cancer proliferation in A549 nonsmall cell lung cancer cells (22), the Craven lab tested the model that PGRMC1
elevates growth factor receptor function. Indeed, PGRMC1 was found to
increase susceptibility to the EGFR inhibitors AG-1478 and erlotinib in the lung
cancer cell line, A549, and the breast cancer cell line, MDA-MB-231 (23). More
specifically, PGRMC1 co-precipitated with EGFR and increased EGFR plasma
membrane levels (Figure 1.3A, lane 3) (23). The PGRMC1-EGFR association
was not altered after EGF stimulation, indicative to a constitutive interaction (23).
To determine EGFR plasma membrane regulation, PGRMC1 was inhibited by
both shRNA and siRNA, and underwent cell surface labeling and
immunofluorescence techniques. EGFR plasma membrane levels were
significantly lower in both RNAi PGRMC1-knockdowns via western blot analysis
(Figure 1.3A, lane 4) (23). Immunofluorescence revealed an increase in the
intracellular pool of EGFR in PGRMC1-knockdown cells (Figure 1.3C) and
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reduction of EGFR at the plasma membrane (23). Additionally, inhibition of
PGRMC1 function by the small molecule inhibitor, AG205, also prevented EGFR
translocation to the cell surface (23). The cellular region in which PGRMC1 and
EGFR co-localize was mapped to the microsomal lumen (Figure 1.4), as both
proteins were found to co-fractionate in the high density fraction in a density
gradient centrifugation (23). Taken together, these data demonstrate a model in
which PGRMC1 associates with EGFR to stabilize EGFR levels at the plasma
membrane (Figure 1.4). It is important to note that PGRMC1 did not regulate the
receptor kinase HER2, suggesting a trafficking specificity (23).
In a separate study published in Nature Communications, crystallographic
and protein analyses further characterized the EGFR-PGRMC1 interaction. Kabe
and colleagues reported that heme is required for PGRMC1 dimerization,
interactions with EGFR, and cancer proliferation and chemoresistance (20).
EGFR and PGRMC1 co-precipitated in human colon cancer cells, and treatment
with succinylacetrone (SA), an inhibitor of heme biosynthesis, disrupted the
interaction (20). The same pattern of PGRMC1 dependence for the trafficking of
EGFR was reported in zebrafish oocyte cell membranes by Thomas and
colleagues (45). Furthermore, treatment with AG205 resulted in a decrease in
EGFR-dependent signaling and EGFR expression (45). These results suggest a
widespread vertebrate generality for EGFR trafficking.
Tumor invasion is a critical step in the spread of cancer, and the
PGRMC1-EGFR complex has been linked to the NGAL-MMP9 complex involved
in tumorigenesis. Neutrophil gelatinase-associated lipocalin (NGAL) is an iron-
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binding protein that forms a complex with and stabilizes the matrix
metalloproteinase MMP9 to promote tumor invasion and survival (46).
PGRMC1 was found to increase the transcription and protein levels of NGAL in
lung cancer cells (46). Additionally, PGRMC1 elevated MMP-9 activity and the
NGAL-MMP9 complex activity (46). NGAL expression was required for tumor
formation, and the EGFR inhibitors erlotinib and AG1478 suppressed NGAL
activity (46). Together these results support the model in which PGRMC1
increases the NGAL-MMP-9 complex by activating EGFR to drive tumor growth
(46).

1.3.5 PGRMC1 and membrane trafficking
In addition to the PGRMC1-EGFR interaction and presence of multiple
immunoreceptor tyrosine-based activation motifs (ITAMs), subsequent studies
have substantiated a role for PGRMC1 in membrane trafficking. PGRMC1 has
been found to associate with membrane progesterone receptor α (mPRα) on cell
membranes (26). Membrane progesterone receptors (mPRs) are seven
transmembrane receptors that belong to the progesterone and adipoQ receptor
family (PAQR), comprising of 5 subtypes. These proteins are expressed on
cellular surfaces, are coupled to G proteins, and initiate a variety of intracellular
signaling pathways associated with G proteins (26). In a study conducted by
Thomas et al., PGRMC1 was found to enhance mPRα expression and function in
both cancerous and noncancerous cell lines, specifically increasing the
availability of mPRα to the plasma membrane (26).
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Analogously to the case with EGFR surface localization, PGRMC1
associates with the glucagon-like peptide-1 receptor (GLP-1R) and mediates
downstream signaling (47). Glucagon-like peptide-1 (GLP-1) is a gastrointestinal
hormone that is secreted by intestinal L cells upon food intake and enhances
glucose-stimulated insulin secretion (GSIS) from pancreatic beta cells (47, 48).
The glucagon-like peptide-1 receptor (GLP-1R) is a member of the large
G protein-coupled receptor family and is involved in glucose homeostasis.
Affinity purification and mass-spectrometry (AP-MS) techniques identified
PGRMC1 as an interactor with GLP-1R, and the direct interaction was confirmed
by co-immunoprecipitation and co-immunofluorescence (47). Furthermore, the
cell surface localization of GLP-1R in pancreatic beta cells was found to be
dependent upon interactions with PGRMC1 (47). Overexpression of PGRMC1
enhanced GLP-1-induced insulin secretion (GIIS) whereas inhibition of
PGRMC1, via RNAi and ligand treatment with AG205, significantly reduced GIIS
(47).
GLP-1R can signal through c-Src to trans-activate EGFR (Figure 1.5), and
an increase in EGFR activity has been linked to increased insulin secretion (47,
49). Zhang et al. found treatment with the epidermal growth factor (EGF)
increased GIIS, and inhibition of EGFR or (downstream) PI3K blocked
PGRMC1’s capability of GIIS (47). The EGFR/PI3K pathway was not found to
mediate GLP-1-induced insulin secretion, therefore suggesting a novel role for
PGRMC1 to participate in PGRMC1-mediated GIIS through EGFR/PI3K to
potentiate insulin exocytosis (Figure 1.5) (47). These results suggest a role for
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PGRMC1 in the maintenance of glucose homeostasis, and more importantly the
involvement in type 2 diabetes, as the insulinotropic properties of GLP-1 are
maintained in patients with type 2 diabetes (47).

1.4 Summary
Over the past two decades, research has compellingly demonstrated roles
for PGRMC1 in heme-binding, steroidogenesis, p450 regulation, tumorigenesis
and membrane trafficking. It has been postulated that PGRMC1 is a signaling
hub protein that may be relevant to multiple disease states and biological
processes (14). In normal tissues, PGRMC1 increases lipid synthesis via
cytochrome p450 proteins. In cancer cell lines, PGRMC1 increases proliferation,
invasion, tumor growth, and renders cells susceptible to oxidative damage.
PGRMC1 is overexpressed in multiple cancers, and associates with tumor
stage and patient survival in ovarian and lung cancer accordingly (43). In this
dissertation, we expand the analysis of PGRMC1 in the clinical setting to include
over 600 tumor sections and lung-tumor derived stem cells. We report the first
clinical analysis of PGRMC1 levels in human oral cavity and ovarian tumors, and
found PGRMC1 expression to correlate with patient survival. Additionally,
PGRMC1 was detected in lung-tumor derived stem cells, and drug treatment with
the PGRMC1 ligand, AG205, triggered stem cell death whereas other treatments
did not.
One of the most note-worthy binding partners of PGRMC1 is the
epidermal growth factor receptor (EGFR), and this association is dependent on
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PGRMC1 binding to heme. PGRMC1 colocalizes with EGFR in the endoplasmic
reticulum (ER) in microsomal vesicles, and is responsible for trafficking the
receptor tyrosine to the plasma membrane (23). Although there are many drugs
that inhibit EGFR, the degree to which patients respond to these drugs varies
markedly between those expressing wild-type EGFR vs mutants of EGFR. My
work investigated multiple signaling-associated pathways that are important in
trafficking wild-type and mutant EGFR with the goal being stimulation of new
approaches to targeting the distinct forms of the receptor.
More recently, PGRMC1 has been linked to GLP-1-induced insulin
secretion via the GLP-1R (glucagon-like peptide-1 receptor). PGRMC1
associates with and activates GLP-1R to enhance the insulinotropic actions of
GLP-1 (49). Furthermore, a global gene expression profile revealed decreased
PGRMC1 RNA levels in insulin-resistant, high BMI patients compared to
matched insulin-sensitive subjects (50). In addition to its highly conserved role in
membrane trafficking, these data support a role for PGRMC1 in the regulation of
glucose metabolism, and my work sought to explore the potential role of
PGRMC1 in trafficking another receptor tyrosine kinase, the insulin receptor (IR).
We report here that PGRMC1 co-precipitates with the insulin receptor (IR)
in multiple cancer cell lines and in an adipose model system. More specifically,
PGRMC1 increases the plasma membrane levels of IR and two glucose
transporters, GLUT-4 and GLUT-1 in cancer cells, with that latter being key
downstream targets of the IR pathway and cellular uptake of glucose. Insulin
binding to IR initiates the translocation of glucose transporters to the plasma
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membrane for glucose entry, and we demonstrate that both insulin binding and
glucose uptake are dependent on PGRMC1. Furthermore, the PGRMC1 ligand,
AG205, was shown to destabilize plasma membrane IR levels in cancer cells,
with no effect on total IR protein levels. Alternatively, treatment with PGRMC1
ligands significantly increased total IR protein levels in fully differentiated human
subcutaneous adipocytes.
The number of pathways affected by PGRMC1 can be expected to include
other functions at various sub-cellular pathways, and the uncharacterized work
should almost certainly provide new future therapeutics for the treatment of
cancer and other diseases (15).
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Figure 1.1 PGRMC1 structure, heme binding and the small molecule AG205.
(Figure legend on following page)
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Figure 1.1 PGRMC1 structure, heme binding and the small molecule AG205.
(A) A model for the human structure of PGRMC1 adapted from Rohe et al., 2009
(See Appendix A for copyright information) (36). Asterisks represent identical
residues between PGRMC1 and Dap1 (yeast homolog), while pound signs
indicate key non-conserved residues. The D120 residue is critical for heme
binding. (B) Close-up view of the binding pocket of PGRMC1 and heme stacking
(adapted from Kabe et al., 2016, see Appendix B for copyright information (20)).
(C) Transition model for structural regulation of PGRMC1 in response to heme
and CO. When heme binds to PGRMC1, a dimer formation can occur between
two PGRMC1 proteins. The presence of CO disrupts the dimer formation
(adapted from Kabe et al., 2016 (20)). (D) The PGRMC1 ligand AG205 chemical
structure and binding to the binding pocket of PGRMC1 (adapted from Yoshitani
et al., 2005, see Appendix C for copyright information (21)).
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Figure 1.2 PGRMC1 promotes tumorigenesis in vivo. A549 cells were
infected with lentiviruses derived from the pGIPZ plasmid (A549/con) or pGIPZ
expressing a short hairpin RNA targeting PGRMC1 (A549/RNAi). Athymic nude
mice were injected with A549/con or A549/RNAi cells. (A) PGRMC1 expression
was inhibited in the excised A549/RNAi tumors (top, lane 2), whereas ku70 was
unchanged. (B) Excised tumor weight of A549/con was 2.9-fold more than
A549/RNAi. (C) A549/con cells efficiently colonized the lungs after tail vein
injection (top, fluorescent image on left and bright field on right), whereas
A549/RNAi cells were deficient in lung colonization (bottom). (D) Graphical
representation of panel C. *, ≤ 0.05; **, ≤ 0.01; ***, ≤ 0.005. (Adapted from
Ahmed et al., 2010a, see Appendix D for copyright information (22)).
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Figure 1.3 PGRMC1 increases EGFR levels at the plasma membrane. (A)
The cell surface proteins of A549/con and A549/RNAi cells were biotin-labeled
with sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate and purified
using avidin-agarose columns. Lanes 1 and 2 and Western blots of the proteins
that failed to bind to the avidin-agarose columns (unbtn), whereas lanes 3 and 4
are Western blots of the avidin-bound proteins (biotin). There was a 7.4-fold
decrease in EGFR at the plasma membrane in A549/RNAi cells (p=0.01) (B-C)
EGFR was stained by immunofluorescence (IF) in A549/con and A549/RNAi
cells, respectively, and indicate an increased intracellular pool of the receptor
(adapted from Ahmed et al., 2010b, see Appendix E for copyright information
(23)).
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Figure 1.4 Membrane trafficking of EGFR directed by PGRMC1. A schematic
representation of PGRMC1 binding to EGFR intracellularly, transporting EGFR to
the plasma membrane for stabilization of the receptor, and the complex
becoming endocytosed and associating together in an endosome.
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Figure 1.5 GLP-1 induced insulin secretion mechanism with PGRMC1 and
EGFR. The diagram shows GLP-1 involved in regulating insulin secretion in
pancreatic beta cells. The blue lines represent the classical way GLP-1R
regulates insulin exocytosis, mainly through cAMP and protein kinase A (PKA)
signaling. The purple lines represent PGRMC1 and its role in increasing GLP-1
induced insulin secretion (GIIS) through activating EGFR and its downstream
PI3K activity (adapted from Zhang et al., 2014, see Appendix E for copyright
information (47)).

25

Oncoscience. PMCID: PMC4278327

CHAPTER II: PATHWAYS DRIVING THE ENDOCYTOSIS OF
MUTANT AND WILD-TYPE EGFR IN CANCER

Kaia K. Hampton and Rolf J Craven

Department of Pharmacology and Nutritional Sciences, University of Kentucky,
Lexington, KY

26

2.1 Introduction

2.1.1 Regulation of wild-type EGFR trafficking
EGFR is over-expressed in a large number of tumors and is one of the
best characterized oncogenic targets. EGFR binds to multiple extracellular
growth factors, triggering conformational changes, dimerization of the receptor
and phosphorylation of numerous residues in its cytoplasmic domain (51, 52).
Some of the phosphorylated sites serve as docking points for downstream
signaling molecules, while others are bound by negative regulatory proteins that
drive endocytosis of the receptor. Specifically, Cbl (Casitas B-lineage
lymphoma), an E3 ubiquitin ligase (53), is recruited to tyrosine 1045
phosphorylated EGFR by the adaptor protein GRB2, which promotes EGFR
ubiquitylation and entrance into clathrin coated pits (Figure 2.1) (54, 55). There
are a number of recent reviews on EGFR signaling and trafficking (56), so we will
focus on several areas acting upstream on wild-type and mutant EGFR that have
not been reviewed recently. MIG6/RALT (mitogen-inducible gene/receptorassociated late transducer) inhibits EGFR (57-61) by associating with the
receptor through a carboxy-terminal ERB-binding region (EBR). MIG6-EGFR
binding physically obstructs EGFR asymmetric dimer formation (58, 61) and
suppresses EGFR activity by stabilizing an inactive conformation of the receptor
(62). Many of these findings were reviewed in 2011 (63). MIG6 decreases
proliferation and migration in a variety of cell types in vitro (63). In MIG6/Errfi1
knockout mice, endogenous EGFR is hyper-activated, causing hyperplasia of
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epidermal keratinocytes and extreme sensitivity to chemical carcinogenesis (64)
that is reversed by gefitinib.
More recently, Hopkins, et al., showed that mammary gland terminal end
buds in Errf1-null mice had increased luminal filling (65). This hyper-proliferation
was not due to EGFR hyper-activation but decreased ABL activity, suppressing
apoptosis in this setting (65). ABL is a cytoplasmic tyrosine kinase associated
with tumor cell survival and metastasis in cancer cells but also with stressassociated apoptosis through p73 in normal tissues (66-68). MIG6 binds to ABL
via its conserved ERB domain in the absence of epidermal growth factor,
suggesting a mechanism in which MIG-6 senses EGF deprivation to induce
apoptosis (65).
In addition to inhibiting EGFR catalytic activity, MIG6 increases EGFR
internalization and trafficking to the lysosome (69), even for EGFR mutants that
are not trafficked by CBL-mediated endocytosis (70). Indeed, computational
modeling suggests that MIG6 and CBL contribute equally to EGFR endocytosis
(71), although this model is based on a limited number of cell lines. MIG6dependent EGFR endocytosis is thought to be clathrin-dependent, involving
binding between MIG6 and the SH3 domains of the intersectins ITSN1 and
ITSN2 (Figure 2.1) (70). Moreover, MIG6 associates with the SNARE protein
syntaxin 8 (STX8, Figure 2.1), elevating levels of the STX8-EGFR complex,
which is essential for EGFR endosomal trafficking (69). The findings of Frosi, et
al. suggests that clathrin-dependent EGFR endocytosis results in lysosomal
degradation (70). However, this model contrasts with a previous study indicating
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that clathrin-dependent EGFR endocytosis is associated with receptor recycling
and sustained activation (72). The latter study employed high levels of ligand,
and the two studies were performed in very different cell types, HeLa (72) and
mouse NR6 cells (70), implying that some aspects of EGFR endocytosis and
signaling may be organism – or cell type-specific. Furthermore, there is recent
biochemical evidence that MIG6 tyrosine phosphorylation weakens its ability to
inhibit EGFR, even though the proteins remain associated (73). Thus, the
activation of various signaling pathways may have a profound effect on CBL
function.
Although some studies suggest that MIG6 and CBL act through separate
mechanisms, other findings suggest interplay between their EGFR endocytic
pathways. Notably, intersectin 1 (ITSN1) forms complexes with both MIG6 and
CBL, mediated by intersectin SH3 domains binding to the proline-rich carboxyterminus of CBL (74) or proline-rich sequences located in the RED (RALT
Endocytic Domain) of MIG6 (70), increasing repression of EGFR signaling (70)
and EGFR ubiquitylation (74). ITSN1, which has been reviewed recently (75),
recruits other proteins downstream, particularly SHP2, SRC homology-2
containing phosphotyrosine phosphatase (Figure 1, (76, 77)).
SPRY2 is a CBL-binding protein (78) that can be tyrosine phosphorylated
(79), driving its association with CBL and inhibiting CBL-RTK binding (Figure 2.1)
(54). SPRY2 is de-phosphorylated by SHP2, releasing CBL (80). ITSN1 recruits
SHP2 to SPRY2, disrupting the inhibitory effect of SPRY2 on CBL, promoting
EGFR ubiquitylation and endocytosis (Figure 2.1) (76). SPRY2 has been
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extensively reviewed elsewhere (81). However, the role of the MIG6-ITSN
complex in regulating CBL- SPRY complex formation is presently unknown.
Thus, the interactions between EGFR, CBL, ITSN and MIG6 may be overlapping,
perhaps to fine tune the temporal signaling through the receptor and to provide
redundancy in the system.

2.1.2 Sigma-2 receptor associates with EGFR, increases plasma membrane
EGFR levels and promotes invasion
PGRMC1 (progesterone receptor membrane component 1) is a
cytochrome b5-related protein that binds heme and is implicated in cellular
trafficking (36). There are compelling data that PGRMC1 is identical to the
sigma-2 receptor (S2R). A highly selective S2R probe cross-linked directly to
PGRMC1; S2R ligand binding decreased with PGRMC1-knockdown and
increased with PGRMC1 over- expression; the apoptotic activity of an S2R ligand
decreased with PGRMC1 knockdown; the PGRMC1 ligand AG205 displaced
S2R ligand binding (22, 82). Notably, PGRMC1 was proposed to be a sigma
receptor more than a decade earlier based on the ability of some sigma ligands
to displace microsomal progesterone binding (83). It is still formally possible that
PGRMC1 is not itself the S2R but is part of a complex that is tightly associated
with S2R, and numerous experiments are under way to further dissect this
possibility. S2RPGRMC1 also plays a key role in membrane-associated
progesterone signaling (12, 84, 85), but S2RPGRMC1 is not homologous to known
steroid receptors and direct binding of progesterone to recombinant PGRMC1
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has not been demonstrated. However, progesterone binding was detected to
partially purified PGRMC1 (85), and RNAi inhibition of PGRMC1 decreased
progesterone binding activity (85) suggesting that S2RPGRMC1 may influence
progesterone signaling through a binding partner. Indeed, Thomas, et al.
demonstrated that PGRMC1 forms a complex with mPRα and recruits the
receptor to the plasma membrane (26). Together, these proteins may be part of
a larger membrane progesterone receptor complex.
In many peripheral tissues and in tumors, numerous groups have localized
S2RPGRMC1 to the endoplasmic reticulum, endosomes, intracellular puncta and
microsomal fractions (3, 23, 27). Interestingly, S2RPGRMC1 localizes to a
significant extent to the plasma membrane (86-88) and nucleus (89) in neuronal
cells, and its interactions with receptors may occur at the plasma membrane in
those tissues. Indeed, it is intriguing to speculate that S2RPGRMC1 might bind to a
membrane progesterone receptor in neuronal tissues, where S2RPGRMC1 is coexpressed with membrane progesterone receptors (87), although this model is
currently untested.
A number of groups have found that S2RPGRMC1 plays a profound role in
regulating cellular signaling, particularly the Akt and ERK pathways (22, 23, 28,
90), and in searching for the mechanism underlying this effect, we found that
S2RPGRMC1 associates with EGFR and co-localizes with EGFR within endosomes
(23). Furthermore, S2RPGRMC1 inhibition decreased plasma membrane levels of
EGFR (Figure 2.1), and EGFR was de-stabilized by S2RPGRMC1 inhibition in
some– but not all – cell types (23). Thus, we propose a model that S2RPGRMC1
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contributes to the trafficking of EGFR to the plasma membrane. An alternate
model is that S2RPGRMC1 inhibits the endocytosis of EGFR, but S2RPGRMC1 was
not detected at the plasma membrane in lung cancer cells (23), suggesting that
any inhibition would be indirect.
Because S2RPGRMC1 associates with EGFR, we searched for downstream
events regulated by this interaction and found that S2RPGRMC1 has a profound
impact on protease activation in lung cancer cells (46). Specifically, the
S2RPGRMC1-EGFR complex increases the Lys310 acetylation and Ser535
phosphorylation of the NF-κB transcription factor, which in turn drives the
expression of NGAL/LCN2 (46), a binding protein for matrix metalloproteinases
such as MMP9 (91). Indeed, MMP9 activity was largely dependent on
S2RPGRMC1 expression in lung cancer cells. These activities required EGFR and
were elevated by exogenous EGFR expression (46). We note that other
proteases, including MMP-2 and cathepsin D, were also activated in an
S2RPGRMC1 -dependent manner (46), and cathepsin D plays a key role in tumor
invasion and metastasis (92).
S2RPGRMC1 is appealing as a cancer target because recent events suggest
that it can be efficiently inhibited both by “PGRMC1” ligands, such as AG205
(21, 22), and by a number of small molecule “sigma-2 receptor” ligands, including
siramesine, PB28, SV119, CB-64D, SM-21 and others (93-98). Some of these
ligands have been extensively tested in vitro, in vivo and in clinical trials and had
relatively minimal side effects. However, it is unclear whether any of these
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ligands alter EGFR trafficking. The interactions between these ligands and
progesterone will likely reveal new elements of the S2RPGRMC1 mechanism.

2.1.3 RAK/FRK increases EGFR trafficking
Our efforts in studying EGFR led to a second heretofore unknown
pathway regulating EGFR trafficking. SRC family intracellular tyrosine kinases
associate with growth factor receptors, including EGFR, and are important in
mitogenic signaling through these receptors (99). Indeed, SRC was the prototypical oncogene, being mutated in transforming avian viruses. There are eight
SRC-related tyrosine kinases with a common SH2 (SRC homology)-SH3 domain
structure and a myristoylation site at the amino terminus (100). The
BRK/RAK/SRC42A/ SRM kinases form a subgroup of proteins called the BRK
family, that are related to SRC structurally but differ in the amino terminal
sequences and multiple other sites (101). In addition, the
BRK/RAK/SRC42A/SRM proteins have widely divergent roles in cell proliferation.
While the majority of SRC-related kinases have a positive role on cell
proliferation and survival, the RAK/ FRK (FYN-related kinase (102, 103) inhibits
growth when expressed in a number of cancer cell types (104, 105). RAK/FRK
phosphorylates and binds to the PTEN tumor suppressor, stabilizing PTEN and
promoting growth arrest, both in vitro and in vivo (106). In addition, RAK/FRK
associates with the RB (retinoblastoma) tumor suppressor (104) and
phosphorylates a negative regulatory site on SRC (102). Thus, there are multiple
potential mechanisms through which RAK/FRK can inhibit cell growth.
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We found that RAK phosphorylated tyrosine 1173 of EGFR and coprecipitated with EGFR (107). The RAK-EGFR interaction required both the SH2
and SH3 domains of RAK and increased after EGF stimulation. As a result, RAK
decreased the levels of EGFR at the plasma membrane (Figure 2.1) (107),
although it is unclear whether this was due to increased EGFR endocytosis,
decreased EGFR transport to the plasma membrane, or some other factor.
Interestingly, BRK/PTK6 (breast tumor kinase/ protein tyrosine kinase 6)
also binds to EGFR and phosphorylates the receptor (108). In addition, BRK
phosphorylates CBL and promotes its degradation (109), potentially decreasing
EGFR endocytosis (Figure 2.1). BRK/PTK6 drives breast tumor formation in vivo
in mouse models (110, 111) and xenografts (111). BRK is also a key effector of
the MET receptor tyrosine kinase (111-113), and its stability is elevated by HER2
(114, 115).
Thus, two closely related RAK-BRK family members associate with EGFR,
although their functions in the complex are opposite. The third family member,
SRC42A, inhibits tyrosine kinase activity in Drosophila (116) in addition to playing
a key role in development. SRM (SRC related kinase lacking C-terminal
regulatory tyrosine and N-terminal myristylation sites) is induced in tumors and
phosphorylates docking protein 11 (117) but does not perform an essential role in
development (118), and any association with EGFR is unknown. It is intriguing to
speculate that the EGFR-BRK and EGFR-RAK complexes (and possibly SRM or
SRC42A complexes in Drosophila) may form in very different environments and
with different dynamics during signaling.
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2.1.4 EGFR mutants drive tumor growth and have altered intracellular
trafficking
Mutant forms of EGFR are associated with cancer development, including
lung cancer in non-smokers, and with elevated sensitivity to EGFR inhibitors
(119-123), such as erlotinib and gefitinib. It has become increasingly clear that
distinct EGFR mutants have different patterns of regulation and trafficking (Table
1). For example, Furukawa, et al. reported that EGFR-∆746-750 has sustained
activation of downstream effectors and is not phosphorylated on Y1045, the CBL
binding site, resulting in impaired endocytosis (124). In the EGFR-L858R
mutant, Y1045 is phosphorylated (121-123). However, in human cancer cells,
EGFR-L858R is down-regulated (125, 126), but their assessment of
ubiquitylation and CBL binding were markedly different (125, 126). In contrast,
Furukawa, et al., found normal EGFR-L858R-CBL binding with unaffected
downstream signaling (124). However, the latter studies were in mouse
fibroblasts and simian COS-7 cells and may not reflect the signaling environment
of cancer cells. The EGFR-L858R mutant has impaired nuclear EGFR
localization resulting in decreased DNA repair activity (127). Interestingly, the
EGFRvIII mutant is also trafficked atypically, with the majority of the receptor
being recycled to the plasma membrane rather than being degraded, even
though the EGFRvIII mutation is on the extracellular surface of the protein (128).
MIG6 expression is elevated in cells expressing EGFR-L858R (129), and
MIG6 is required for the endocytosis of wild-type and mutant EGFR (129, 130).
However, MIG6 tyrosine phosphorylation is elevated in cells expressing EGFR35

L858R and EGFR-∆746-750 (131), suggesting a weaker ability to inhibit the
receptor (Table 1). SPRY2 prevents endocytosis of both wild- type and ∆746749/A750 mutant EGFR (130). Thus, in a limited number of cell lines, MIG6 and
SPRY2 do not discriminate between wild-type and mutant EGFR in their
endocytic functions (130). However, a recent study suggests that, although
MIG6 is more efficient against the wild- type EGFR, it has an increased role in
the endocytosis of EGFR ∆746-A750 compared to wild-type EGFR, because
CBL is less active against the mutant (71). The EGFR- vIII mutant does not
undergo ligand-induced endocytosis due to low levels of phosphorylation (132),
and MIG6 is inactive against it (69).
In contrast to MIG6 and SPRY, S2RPGRMC1 does not act equally on wildtype and mutant EGFR. An S2RPGRMC1 inhibitor was active against cells
expressing wild-type EGFR, but had no activity against lung cancer cells
expressing EGFR mutant (23). However, the cell lines had different genetic
backgrounds, and factors other than EGFR could have affected S2RPGRMC1
inhibitor sensitivity. For that reason, we expressed wild-type EGFR and the
EGFR-∆747-749/A750P mutant in MDA-MB-435 cells, which do not express
EGFR, and found that S2RPGRMC1 co- precipitated with wild-type EGFR-2.4-fold
more than the mutant (Figure 2.2). The mechanism underlying this specificity is
unclear. However, S2RPGRMC1 is enriched in endosomes in lung cancer cells (23),
and the decreased endocytosis of mutant EGFR may limit the access of the two
receptors to each other. Because S2RPGRMC1 binds mutant EGFR poorly (and
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inhibitors are inactive against cells expressing it), we do not expect that S2R
functions through a SPRY pathway for EGFR regulation.
In stark contrast to S2RPGRMC1, we found that RAK/ FRK bound
preferentially to the EGFR ∆746-749/A750P mutant compared to the wild-type
protein (107). This may be due to the increased activity of the mutant EGFR,
because RAK binding to wild-type EGFR increased after ligand stimulation (107).
The results suggest that RAK may have elevated tumor suppressive activity in
tissues expressing mutant EGFR. It is intriguing to speculate that tumors
expressing mutant EGFR may have decreased RAK expression, but this concept
has not been tested. Because RAK and MIG6 are both active against EGFR
mutants, it is intriguing to speculate that they may be mechanistically related.
However, this remains to be tested.

2.2 Perspectives: Current and Future Work
Mutant forms of EGFR are associated with some types of cancer and
have differential trafficking compared to the wild-type receptor. Furthermore,
specific trafficking proteins are distinct in their regulation of wild-type and mutant
EGFR. In spite of the dramatic advances in the field, there are numerous
questions remaining about MIG6, such as the conditions under which its tyrosine
phosphorylation changes and the key players directing these alterations. In
addition, new targets for MIG6 play key roles in proliferation and apoptosis. In
normal tissues lacking MIG6, breast cells proliferated due to loss of ABL (65), but
it is unclear how the MIG6-ABL interaction changes in different non-malignant
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cell types and during cancer progression. In normal tissues, ABL is thought to be
pro-apoptotic, while in cancer cells, ABL drives proliferation, survival and
metastasis. But it is unknown whether ABL no longer binds MIG6 in cancer cells
or whether binding changes in the presence of apoptotic stimuli.
The relatively poor binding of S2RPGRMC1 to the EGFR-∆746-749/A750P
mutant (Figure 2.2) may offer important clues to its interaction with EGFR. If the
mutant is sustained at the plasma membrane, it is likely that S2RPGRMC1 is
prevented from binding to mutant EGFR because EGFR is not internalized,
consistent with the endosomal localization of S2RPGRMC1 in lung cancer cells (23).
For wild-type EGFR, EGF stimulation did not affect EGFR-S2RPGRMC1 binding
(23), suggesting that the activated state of EGFR-∆746-749/A750P is not
responsible for the change in binding to S2RPGRMC1. Future work will include a
broader analysis of S2RPGRMC1 binding to additional EGFR mutants, particularly
EGFR-L858R.
The RAK/FRK tyrosine kinase decreases the plasma membrane pools of
EGFR, and it is intriguing to speculate that RAK/FRK might influence the
phosphorylation of EGFR trafficking proteins, including SPRY2, MIG6 and ITSN.
We predict that RAK/FRK would increase MIG6 activity, possibly by decreasing
MIG6 tyrosine phosphorylation. Conversely, we speculate that RAK/ FRK might
decrease the tyrosine phosphorylation of SPRY2, because SPRY2
phosphorylation is associated with decreased EGFR ubiquitylation (Figure 2.1).
Current research is focusing on the role of RAK/FRK-PTEN binding in regulating
EGFR.
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2.3 Conclusions
EGFR levels at the plasma membrane are balanced by competing positive
and negative mediators. The impact of these pathways changes for the mutant
forms of the receptor, and some of the regulatory proteins have altered
expression in cancer. While kinase inhibitors are active against tumors
expressing mutant EGFR, their activity is limited against those expressing wildtype EGFR, and some activities of EGFR may be kinase-independent.
S2RPGRMC1 inhibitors are attractive in this setting because they inhibit EGFRdependent cancer cell proliferation and are most active against the wild-type form
of the protein (23).
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Table 1 EGFR-L858R and EGFR-∆746-750 mutants differ from wild-type
EGFR in regulation and trafficking. Question marks indicate unknown, and a
negative sign implies no effect.

Endocytosis by MIG6
Endocytosis by RAK
Prevents endocytosis by SPRY2
S2R association
Sensitivity to S2R inhibitor
MIG6 Expression
MIG6 tyrosine phosphorylation
Impaired nuclear localization
CBL association

Wild-type
+++
+
+++
+++
+++
+
+
++
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L858R
+++
?
?
?
?
++
++
+
++

∆746-750
+++
+++
+++
+/?
++
?
-

Figure 2.1 Selected pathways regulating EGFR endocytosis and
degradation. In the top panel, EGFR levels at the plasma membrane are
increased by S2RPGRMC1. The diagrams, from left to right, below, show different
binding partners for EGFR. GRB2 recruits CBL to EGFR resulting in lysosomal
degradation. SPRY2 phosphorylation drives its association with CBL, inhibiting
CBL binding to EGFR. ITSN1 can recruit SHP2 to dephosphorylate SPRY2,
releasing CBL to bind EGFR. MIG6 physically obstructs EGFR dimerization and
binds to STX8 and ITSN1/2 to promote lysosomal degradation of EGFR. BRK
phosphorylates EGFR to inhibit EGFR internalization, while RAK/FRK has the
opposite activity.
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Figure 2.2 S2RPGRMC1 preferentially associates with wild-type EGFR.
MDA-MB-435 human breast cancer cells, which do not express EGFR (lower
panel, lane 1), were transfected with a control plasmid (lane 1), the plasmid
pcDNA3.1-EGFR (lane 2, a gift from Drs. Penni Black, University of Kentucky,
and William Pao, Vanderbilt University) or the plasmid pBabe-EGFR-∆746749/A750P Addgene, Cambridge, MA). In the top two panels, lysates were
immuno-precipitated using previously described conditions (23) with the antiEGFR antibody IMC-C225 (Erbitux, ImClone Systems, Branchburg, NJ).
Precipitates were then analyzed by western blot with (top panel) the antiS2RPGRMC1 antibody PGR-UK1 (22) or (middle panel) an anti-EGFR polyclonal
antibody (1005, Santa Cruz Biotechnology). Because of the very different
molecular weights of the proteins, the blot was cut in half before probing. The
bottom panels show the same unprecipitated cell lysates that were used for the
precipitation reactions analyzed by western blot using EGFR and GAPDH
polyclonal antibodies, the latter as a control for protein loading. The result shown
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is representative of three independent experiments. We have previously shown
that the EGFR-∆746-749/A750P mutant is highly tyrosine phosphorylated in this
system compared to wild-type EGFR (107).
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3.1 Introduction
PGRMC1 is induced in a number of cancer types (36), including breast,
ovarian and lung cancers, and a small study indicated that PGRMC1 is
associated with poor survival in lung adenocarcinoma (43). PGRMC1 is also
expressed in sebaceous carcinomas (133). PGRMC1 plays a causative role in
cancer progression, because in vitro, PGRMC1 increases tumor cell proliferation,
chemotherapy resistance and invasion, and in vivo, PGRMC1 increases tumor
growth, angiogenesis and metastasis (12, 22, 134-137). There are a number of
potential mechanisms through which PGRMC1 might promote tumor growth.
PGRMC1 associates with the epidermal growth factor receptor (EGFR) and
regulates susceptibility to the EGFR inhibitor erlotinib by increasing plasma
membrane pools of EGFR (23). PGRMC1 also increases EGFR levels in
Zebrafish (45). In lung cancer cells, the EGFR- PGRMC1 complex drives
invasion, at least in part, by activating matrix metalloproteinases (46).
PGRMC1 is also detected in the nucleus in some cell types, where it
regulates transcription (31) and in the centromeric region of chromosomes during
oocyte meiosis (29, 30). PGRMC1 also localizes to the actin cytoskeleton and
binds actin. In lung cancer cells, the prominent localization for PGRMC1 is
cytoplasmic puncta, including early endosomes, and numerous groups have
reported similar findings in other cell types. Finally, PGRMC1 is secreted by lung
cancer cells, where it has a pro-proliferative function, and is detected in the
plasma of lung cancer patients (138).
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There is a growing consensus that PGRMC1 is critical for the transport of
specific receptors to the plasma membrane. The receptors include EGFR,
GLP1R, glucagon-like peptide 1 receptor (47), and mPR1α, membrane
progesterone receptor α (26). PGRMC1 binds to mPR1α and transports it to the
plasma membrane (26). Indeed, PGRMC1 was originally identified as a putative
hormone receptor or “receptor membrane component” (3, 4, 10). Partially
purified PGRMC1 binds to progesterone (25, 85), and recently, progesterone
binding by recombinant PGRMC1 was reported (19), suggesting a direct role for
PGRMC1 in progesterone function. PGRMC1 has an established role in
progesterone signaling (12, 84, 134), and in some diseases, such as breast
cancer, this contributes to hormonal growth and anti-apoptotic signaling (139).
However, PGRMC1 shares no homology with hormone receptors (13) but has
motifs that are structurally related to cytochrome b5, and PGRMC1 binds heme
(7, 13, 16, 24, 32, 34, 140, 141), an evolutionarily conserved function (32, 34,
142) that is distinct from progesterone binding (19).
According to the cancer stem cell theory, tumors contain a sub-population
of cells with extended replicative potential that contribute to drug resistance (143,
144). Cancer stem cells are thought to arise from mutations to either normal
stem cells or transit amplifying cells, with key signaling contributions from the
tumor microenvironment. PGRMC1 is detectable in amniotic-derived
mesenchymal cells (145) and has been identified as an important hormonal
signaling intermediate in neuronal stem cells (84), but its expression and function
in cancer-derived stem cells have not been determined.
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We demonstrate here that PGRMC1 is elevated in multiple tumor types,
including head and neck cancer and in oral cancer. Using immunohistochemistry
of paraffin-embedded tissue, we also confirm previous findings from western
blots of frozen tissue that PGRMC1 staining correlated with survival in lung
cancer patients. According to the stem cell theory, cancer stem cells are critical
for the long-term survival of a tumor population and its therapeutic resistance.
We report here that PGRMC1 is abundant in lung cancer-derived stem cells from
patients, and PGRMC1 inhibition triggered cell death in lung cancer stem cells
where other therapeutic classes failed.

3.2 Materials and Methods

3.2.1 Tissue arrays
The tissue arrays used were as follows. For head and neck cancers:
HN483, HN242a and HN802 (US Biomax, Inc. Rockville, MD). For oral cancer,
OR802 (US Biomax, Inc.). For lung cancer, BC04011, BC041114, BS04011,
LC991 (US Biomax), IMH-305 and IMH-340 (Imgenex, Inc., San Diego, CA). For
ovarian cancer, BC11115 and OV951 (US Biomax).

3.2.2 Immunological reagents and techniques
Tissue arrays were stained with an anti-PGRMC1 antibody raised to a
recombinant protein composed of amino acids 43-195 of PGRMC1 (ProteinTech
Group, Inc., Chicago IL). Immunohistochemistry was performed by the
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University of Kentucky Histology Laboratory using the Dako Envision kit
(Carpinteria, CA) and following the manufacturer’s instructions. Staining was
analyzed and scored by a board-certified pathologist (Dr. Stewart), as well as
other authors, and analyzed statistically using Microsoft Excel. Kaplan-Meier
curves were analyzed and prepared using Graphpad Prism software. Blocking
was performed with an equimolar concentration of purified, recombinant
PGRMC1-glutathione S-transferase fusion protein spanning the antigenic region,
and the protein has been described (16).
Protein levels were analyzed by western blot as previously described (40),
blotting electrophoresed proteins to Immobilon-P membranes and developing
using the West Pico chemiluminescent substrate (Pierce). Blots were performed
at least in duplicate. The antibodies used were the following: anti-GAPDH (Santa
Cruz, FL-335), anti-LCB (Cell Signaling, D11), anti-SQSTMI/p62 (Cell Signaling,
5114), anti-caspase 3 (Santa Cruz, sc-7138), anti-PARP (Santa Cruz, sc-7150)
and anti-PGRMC1 (22).

3.2.3 Lung cancer stem cells
Single-cell suspensions were isolated from patients at the Edwards
Cancer Center using a gentleMACS Dissociator (Miltenyi, Auburn, CA), and C
Tubes using a standardized, semi-automated protocol based on a combination of
mechanical tissue disruption and incubation with a 50% solution 0.025% trypsin
and Accutase (Innovative Cell Technologies, San Diego, CA). Cells were serially
plated in 12-well, 6-well, 10-cm treated dishes and cultured to subconfluence in
48

RPMI-1640 medium supplemented with 5% irradiated, heat inactivated, defined
fetal bovine serum (Thermofisher/Hyclone), and 50 U of penicillin and 5 mg of
streptomycin/mL of medium (Thermofisher/Mediatech). Cancer stem cells were
selected and proliferated using a hydrodynamic focusing bioreactor as previously
described (146). After seven days of growth in the bioreactor, cells were then
removed and counted using a CelloMeter automated counter and trypan blue
exclusion to determine cellular viability and cell number. Cells were then
immunophenotyped using fluoresceinated antibodies to CD133, CD44, CD24
and CXCR4 with an Accuri C-6 flow cytometer. For live cell assays, lung tumorderived stem cells (positive for CD133, CD43, SSEA3/4, Oct4, alkaline
phosphatase, aldehyde dehydrogenase and telomerase) were purchased from
Celprogen, Inc. and were maintained in Human Lung Cancer Stem Cell
Complete Growth Media with serum (Celprogen, Inc., Torrance, CA).
Cell viability was determined by Cell Titer Blue Cell Viability Assay
(Promega). Erlotinib was from LC Laboratories (Woburn, MA), and other
treatments were LY294002 (Sigma), PD98059 (Sigma) and AG205 (Tocris). For
drug treatments, cells were maintained in complete media and switched to serum
free media (DMEM containing antibiotics) and various drugs for 24 hours. For
microscopy, cells were treated with vehicle or 10 μM AG205 for an additional 24
hours. Bright-field images were captured on a Nikon Eclipse TE200 microscope
at 20x magnification. For viability assays, cells were treated for 72 hours in
complete media, and viability was assayed according to the manufacturer’s
instructions. Absorbance was measured using a Spectra Max M2
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spectrophotometer (Molecular Devices). For western blot analysis, cells were
lysed in radioimmunoprecipitation buffer containing protease inhibitors and
phosphatase inhibitors.
For dye exclusion, cells were trypsinized and treated with 5 μg/ml Hoechst
33342 (Sigma) at 37°C for 45 minutes. Cells were then washed with PBS
(Gibco) and incubated in fresh media for 45 minutes at 37°C to allow for dye
efflux before being centrifuged and analyzed again by FACS.

3.3 Results

3.3.1 PGRMC1 in airway cancers
PGRMC1 is essential for lung tumor formation and metastasis, so we
determined PGRMC1 levels by immunohistochemistry in 330 lung cancer
samples using tissue microarrays, which included 58 patients with survival data.
Tissues were stained for PGRMC1 and scored by a board-certified Pathologist.
The antibody- generated to amino acids 43-195 of PGRMC1- was a commercial
product from Proteintech Group, and to our knowledge, no controls for staining
have been performed with this product. In staining of a tissue from an earlier
study, we found that recombinant PGRMC1 fusion protein blocked staining with
the antibody, suggesting that it is specific (Figure 3.1 A-B).
Consistent with earlier western blotting studies (43), PGRMC1 was
significantly higher in lung tumors than normal tissue (p=2 X 10-7, 2-sided t-test)
and was higher in stage I tumors compared to stage II (p=3X10-5, 2-sided t-test)
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but was not associated with age at diagnosis or gender. High PGRMC1expressing tumors had a significantly worse overall survival (p=0.02 by GehanBreslow-Wilcoxon test), with median survival times of 25 months for high
expressers versus 108 for low expressers (Figure 3.2 A).
PGRMC1 staining was analyzed in 173 tissues from the head and neck,
including the oral cavity, in tissue microarrays. Tumors from multiple sites within
the head and neck region stained strongly for PGRMC1 (Figure 3.1 C-F),
including tumors of the submaxilla, cheek, parotid gland, gingiva and larynx
(Figure 3.4). PGRMC1 was significantly elevated in all head and neck tumors
(n=173) compared to corresponding normal tissues (n=23, p=0.004, 2-sided ttest). There was no association with stage or gender, but PGRMC1 staining was
higher in tumors from patients younger than 60 (p=0.03, n=113). For example,
the highest levels of staining were located in the tongue, and PGRMC1 was
elevated in tongue tumors (n=16, Figure 3.1 C-D) relative to normal tongue tissue
(n=18, p=0.009).

3.3.2 PGRMC1 in ovarian cancer
In ovarian tissues, PGRMC1 staining was not significantly different in
normal ovarian tissue compared to tumor adjacent tissue, clear cell carcinomas
or mucinous papillary adenocarcinomas (Figure 3.1G). In contrast, PGRMC1
was significantly elevated in serous papillary adenocarcinoma (p=4 X 10-5),
papillary serous cystadenocarcinoma (Figure 1.H, p=0.006) and endometroid
carcinoma (p=0.02, Figure 3.5). PGRMC1 was also elevated in metastatic
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serous papillary adenocarcinoma compared to normal tissue (p=0.003), but was
not significantly different from the primary serous papillary adenocarcinoma. This
difference was highly significant (Figure 3.2B, p=0.0011 by Mantel-Cox test and
0.0014 by Gehan-Breslow-Wilcoxon test).

3.3.3 PGRMC1 in cancer-derived stem cells
The association between PGRMC1 levels and tumors suggested a
potential role for PGRMC1 in stem cell maintenance. Stem cells were isolated
from surgical specimens at Marshall University using a PBRX bioreactor, and
western blots revealed abundant PGRMC1 in isolated stem cells as well as in the
bulk of the tumor (Figure 3.3A). The isolated stem cells were pre-screened for
expression of CD133, CD44, CD24 and CXCR4 as described (146).
To assess the role of PGRMC1 in stem cell viability, we treated lung
tumor-derived stem cells with the PGRMC1 ligand AG205 (22), which had an
IC50 of 95 μM (Figure 3.3B, solid lines), and induced cell rounding (Figure 3.3C).
In contrast, stem cells were highly resistant to the EGFR inhibitor erlotinib, a
widely used drug for lung cancer, and the ERK inhibitor PD98059, which is active
against a variety of cancer cell lines (Figure 3.3B, dashed lines). Because the
cells rounded and detached, apoptosis is a potential cell death mechanism, but
AG205 treatment did not cause changes in markers of apoptosis, including
cleavage of PARP and caspase-3 (Figure 3.6). The ability to efflux dyes is a key
marker of cancer stem cells, and we found that lung cancer stem cells had the
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properties typical of a “side scatter” population (Figure 3.7). However, drug efflux
did not change with AG205 treatment.
In some cases, autophagy can be a cell death mechanism that acts as an
alternative to apoptosis (147), and PGRMC1 has been implicated in autophagy
(138), a metabolic process in which aged proteins and organelles are degraded
in the lysosome (148). LC3B is both a key mediator of autophagy and an
autophagy substrate that is cleaved and lipidated to the mature LC3B-II form.
We detected increased levels of LC3B-II upon PGRMC1 ligand treatment,
suggesting that autophagy was induced (Figure 3.3D, top panel). PGRMC1
ligands induce autophagy in lung cancer but also arrest the process, so that
autophagy substrates are not degraded. In stem cells, PGRMC1 ligand
treatment increased LC3B-II levels but did not decrease levels of the autophagy
substrate p62. The autophagy inhibitor chloroquine behaved similarly (data not
shown), consistent with an autophagy arrest in cancer stem cells treated with
PGRMC1 ligands. However, it is unlikely that autophagy arrest caused cell
death, because chloroquine had no effect on cell viability. Notably, AG205
caused an increase in PGRMC1 levels (Figure 3.3D, third panel), suggesting that
AG205 alters PGRMC1 stability.

3.4 Discussion
PGRMC1 is a membrane-associated protein implicated in the transport of
multiple receptors to the plasma membrane, and multiple studies have proposed
PGRMC1 ligands as therapeutics or diagnostic agents for cancer. In the present
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study, we demonstrate that PGRMC1 was elevated in a large cohort of lung
tumors, which included multiple lung cancer pathologies, and where it was
associated with poor survival. To our knowledge, this is also the first report of
PGRMC1 expression in the oral cavity, and we detected strong PGRMC1
expression in multiple organs, particularly in the tongue. In some tissues,
PGRMC1 was enhanced on the outer surface of the tissue (Figure 3.1C),
suggesting a role in secretion or trafficking. Indeed, PGRMC1 is secreted in lung
tumors (43).
This is, to our knowledge, the first report of PGRMC1 expression in a
relatively large cohort of ovarian cancers. PGRMC1 has been previously shown
to play a key role in ovarian tumor growth, apoptosis resistance, invasion,
angiogenesis, drug resistance and metastasis (25, 134, 149-152). There are
also numerous reports linking PGRMC1 to normal ovarian function, including
follicle development (153, 154), and is aberrant in premature ovarian failure
(155). Thus, the finding that high PGRMC1-expressing tumors correlate with
poor overall survival emphasizes the importance of PGRMC1 as a therapeutic
target in ovarian cancer.
The current study is, to our knowledge, the first report of PGRMC1
expression in cancer stem cells. PGRMC1 was detected in stem cells isolated
using two different approaches, and the second commercial source was verified
by measuring dye exclusion. The ability of the PGRMC1 ligand AG205 to induce
rounding and inhibit viability in the stem cells differed markedly from known
inhibitors. The mechanism through which PGRMC1 functions in the cells is
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enigmatic, because EGFR inhibition had no effect on tumor stem cell growth, and
the cells did not die from apoptosis. We were also unable to detect changes in
signaling (i.e. global tyrosine phosphorylation), protein degradation (ubiquinated
protein levels) and PGRMC1-sensitive metabolism (INSIG-1 and CYP51 levels).
AG205 treatment induced the early event of autophagy, LC3-II accumulation, but
autophagy inhibition with chloroquine did not affect viability, suggesting that other
mechanisms are at work. We are currently investigating candidate mechanisms
in signaling and metabolism.
PGRMC1 was identified as the sigma-2 receptor in 2011, and there is an
ongoing, vigorous debate as to whether the proteins are identical. The sigma-2
receptor (S2R) is a membrane-associated protein that binds a number of
pharmacological compounds, including signature ligands SV-119, siramesine,
SM-21 and PB-28 (156-159), among others, as well as multiple anti-depressants
and stimulants. S2R and PGRMC1 have very similar patterns of being induced in
cancer, and S2R is detectable in stem cells. Xu, et al. identified PGRMC1 based
on its ability to bind and cross-link to the ligand WC-21 (82). The sigma-2
receptor probe RMH-4 was competed by classical S2R ligands, such as DTG,
siramesine, SV119 and WC-26, and equally by the PGRMC1 ligand AG205 (82).
Furthermore, RNAi knockdown of PGRMC1 in HeLa cells decreased binding of
labeled RMH-4, while PGRMC1 over-expression increased binding (82).
In contrast to the reports of the Mach group and co-workers, Abate, et al.
demonstrated that PGRMC1 knockdown in MCF-7 breast cancer cells did not
affect DTG (1,3-di-o-tolylguanidine) binding in membrane fractions (160). At the
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moment, it is difficult to reconcile these findings, except that they were performed
with different cell lines and ligands. In addition, Chu, et al. recently showed that
PGRMC1 knockout in NSC34 cells did not affect binding of DTG or photolabeling
of the 18 kDa “S2R” with [125I]-Iodo-azido-fenpropriomorph. Based on these
findings, the authors stated in the title of the paper that “The sigma-2 receptor
and the progesterone receptor membrane component 1 are different binding
sites derived from different genes”. There are some caveats. NSC34 cells are a
hybrid of mouse embryonic spinal cord cells and mouse neuroblastoma cells and
represent a very specialized example of cell biology, as do HeLa and PC12 cells.
As a compromise, it could be argued that the sigma-2 receptor is a
separate entity from PGRMC1, but S2R-ligand binding requires PGRMC1,
perhaps due to a direct interaction between S2R and PGRMC1. However, this is
not consistent with the ability of IAF to photolabel S2R equally in control and
PGRMC1-knockout cells. Another possibility is that the original probe, WC-21,
has non-S2R binding activity, including binding to a PGRMC1 complex. However,
the ability of multiple well characterized S2R ligands to efficiently compete for
WC-21 binding argues against this possibility (82). Clearly, there are many
questions to be addressed in this field, including the identity of the 18 kDa “S2R”
protein, and we have used the nomenclature “PGRMC1” in this study until the
situation is resolved.
In summary, the present findings implicate elevated PGRMC1 expression
in a broad range of tumor types. Tumors of the upper airways are intriguing for
therapeutics, because topical delivery systems can allow greater penetrance of

56

chemicals and biologicals targeting PGRMC1. In addition, we provide evidence
linking PGRMC1 expression to cancer stem cells, which are notorious for their
resistance to therapeutics, and the cancer stem cells in this study were highly
resistant to powerful agents such as erlotinib and PD98059. In contrast,
PGRMC1 inhibitors had activity against cancer stem cells, suggesting a role for
PGRMC1 in maintaining cancer stem cell viability. In contrast, PGRMC1
inhibitors had activity against cancer stem cells, suggesting a role for PGRMC1
in cancer stem cell maintenance and the importance for inhibitors such as AG205
for future therapeutics targeting cancer stem cells.

3.5 Conclusion
PGRMC1 is broadly expressed in a variety of tumors, where its expression
is elevated in comparison to corresponding normal tissues. In some diseases,
PGRMC1 expression correlates with poor patient survival, while in breast cancer,
the correlation between PGRMC1 and survival is more complex and may depend
on the patient population or epitopes being analyzed. PGRMC1 was expressed
in two different patient-derived tumor stem cell populations and was required for
viability in those cells. The results support PGRMC1 as a tumor biomarker and
therapeutic target for multiple types of cancer.
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Figure 3.1 Immunohistochemistry of PGRMC1 in multiple tissues.
Immunohistochemistry of (A) a lung tumor section using the anti-PGRMC1
antibody 12990 from Proteintech Group, Inc. (B) The same section stained with
the same antibody plus recombinant PGRMC1 fusion protein. (C-H) PGRMC1
staining in multiple tissues, as indicated in the figure.
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Figure 3.2 PGRMC1 correlates with patient survival. (A) Kaplan-Meier plot in
samples from patients with lung cancer, comparing high PGRMC1 staining
tumors (solid line) with low PGRMC1 staining tumors (dashed line). (B) A similar
analysis to panel a, for ovarian cancers.

59

Figure 3.3 Treatment with AG205 reduces stem cell viability. (Figure legend
on following page)
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Figure 3.3 Treatment with AG205 reduces stem cell viability. (A) Bulk tumor
cells and tumor stem cells were isolated from a patient with lung cancer and
analyzed by western blot for PGRMC1 (upper panel) and GAPDH (lower panel,
loading control). PGRMC1 was abundant in both the bulk tumor cells and the
stem cells. (B) Cancer-derived stem cells were treated with various ligands and
assayed for viability. Neither the EGFR inhibitor erlotinib nor the ERK inhibitor
PD98059 were active against the cells, while the PGRMC1 ligand AG205
inhibited viability of the cells. (C) Bright field imaging of cancer-derived stem
cells treated with AG205 revealed cell rounding in the majority of the cells. (D)
Western blot analysis of stem cells treated with vehicle (lane 1) or AG205 (lane
2) revealed increased levels of the autophagy initiating protein LC3B-II (top
panel, lower band), while the levels of the autophagy substrate p62 were
unchanged (second panel). PGRMC1 levels increased following treatment (third
panel), and GAPDH served as a loading control.

61

Figure 3.4 Immunohistochemistry of tumors and tissue from the head and
neck region. (A) Squamous cell carcinoma of right submaxilla, stage II. (B)
Squamous cell carcinoma of left cheek, stage II. (C) Squamous cell carcinoma
with necrosis of right parotid gland, stage II. (D) Mucoepidermoid carcinoma of
gingiva, stage I. (E) Squamous cell carcinoma of larynx, stage IV. (F) Normal
larynx tissue.
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Figure 3.5 Immunohistochemistry of ovarian tumors and tissue. (A) Clear
cell carcinoma, stage IIB. (B) Endometrioid carcinoma, stage IIB. (C) Papillary
serous cystadenocarcinoma, stage IIB. (D) Papillary serous
cystadenocarcinoma, stage IIIC. (E) Serous surface papillary carcinoma. (F)
Normal ovary tissue.
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Figure 3.6 Treatment with AG205 did not induce apoptosis. Western blot
analysis of stem cells treated with vehicle (lane 1) or 10 μM AG205 (lane 2), as
described in the methods section. Treatment with PGRMC1 ligand AG205 did not
induce cleavage of PARP (top panel) or caspase-3 (middle panel), which are
common apoptosis markers. GAPDH (bottom panel) served as a loading control.
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Figure 3.7 Measurements of drug efflux in lung cancer stem cells. Drug
efflux pattern of lung cancer stem cells follows typical “side scatter” population.
Lung cancer-derived stem cells were treated with vehicle control (A) or Hoechst
33342 (B-D). In panel B, there were no further treatments, whereas cells were
treated with 50 μM AG205 for 24 hours (C) or 48 hours (D). In triplicate
measurements, drug treatment did not affect dye exclusion to a significant extent.
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4.1 Introduction
Changes in insulin signaling have been linked to multiple diseases, most
typically diabetes (161) but also loss of cognitive function (162) and therapeutic
resistance in cancer (163, 164). More recently, a growing body of evidence has
demonstrated the importance of IR expression in cancer cell proliferation and
tumor development (165). IR is a tetramer comprised of 2 alpha (ligand binding)
and 2 beta (kinase domain) chains that is expressed in numerous tissues. The
human IR encodes two isoforms, IR-A (lacking exon 11) and IR-B, with the latter
having a predominant role in metabolic insulin action (166).
Signaling from the IR through the IRS-1/PI3K/AKT pathway causes a rapid
translocation of the GLUT-4 glucose transporter from intracellular vesicles to the
plasma membrane (167), increasing the cellular uptake of glucose (168), a step
that is crucial to preventing complications of multiple diseases.
IR is actively transported in a cycle of plasma membrane export, activation
and internalization (169-172) and disruptions to this cycle are a candidate
mechanism for insulin resistance. IR is internalized after ligand binding through
clathrin-dependent (173, 174) or caveolin-dependent (175) mechanisms that
govern the degradation and recycling of the receptor complex (176, 177). While
the signaling pathways downstream of insulin binding are quite well
characterized, the proteins driving the plasma membrane localization of IR are
less well understood.
PGRMC1 (progesterone receptor membrane component 1 (1) plays an
important role in signaling by transporting transmembrane receptors to the
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plasma membrane (26, 178), and these receptors include tyrosine kinases (26,
47). PGRMC1 localizes to endosomes and the endoplasmic reticulum (27, 36),
as well as the plasma membrane (86), consistent with its highly conserved role in
trafficking. In cancer, the best characterized trafficking target for PGRMC1 is the
EGFR (epidermal growth factor receptor) tyrosine kinase (20, 23, 45, 46), and
PGRMC1 increases plasma membrane levels of EGFR (23), increasing cellular
signaling (22, 28, 90). In contrast, the EGFR-related protein HER2/neu was not
PGRMC1-dependent (23), suggesting a trafficking specificity.
In addition to tyrosine kinases, PGRMC1 also increases plasma
membrane pools of GLP-1R and MPRα1, a plasma membrane progesterone
receptor (26, 47). The latter likely contributes to progesterone binding activity by
the PGRMC1 complex, which was how PGRMC1 was originally identified (3, 4,
10, 83). Some types of progesterone signaling are dependent on PGRMC1 in
diverse regions of the body, including the brain, ovaries and the pancreas (179182). Binding to the liganded GLP-1R complex likely contributes to glucose
homeostasis, as PGRMC1 has been found to modulate glucose-induced insulin
stimulation in beta cells (47).
PGRMC1 has numerous other binding partners, including cytochrome
P450 proteins (32, 33, 183), PAIR-BP1 (plasminogen activator inhibitor RNA
binding protein 1 (182, 184)) and α-tubulin (30). PGRMC1 is attractive as a
therapeutic target because it has a small molecule ligand, called AG205 (22) that
was identified by our group and has been verified as a PGRMC1-targeting ligand
by others (18, 22, 45, 47, 82).
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In the present study, we have investigated the role of PGRMC1 in
trafficking IR and promoting glucose uptake. There is a precedent for PGRMC1
being associated with insulin signaling, because a clinical study of insulinresistant, high BMI subjects demonstrated decreased PGRMC1 RNA levels
compared to insulin-sensitive subjects (185). However, this study did not provide
a direct link between IR and PGRMC1. Based on previous findings by our group
that PGRMC1 regulated receptor tyrosine kinase trafficking, we posited that
down-regulated PGRMC1 could disrupt normal IR function. In the results, we
show that PGRMC1 has a direct role in regulating IR trafficking and glucose
transport.

4.2 Methods

4.2.1 Tissue Culture
A549 cells were obtained from ATCC (Manassas, VA) and verified by
Genetica LLC (Cincinnati, OH). HUH7 cells were generously provided by Dr.
Brett Spear (University of Kentucky College of Medicine). Cells were maintained
in DMEM (Corning, Manassas, VA) containing 10% fetal bovine serum (FBS)
(Sigma Aldrich, St. Louis, MO) and antibiotics and were maintained at 37°C in
5% CO2 and air. The A549 derivatives infected with lentiviruses expressing short
hairpin RNAs were prepared from the plasmids pGIPZ (control) and
V2LHS_90636 (PGRMC1-knockdown) and have been previously described (23).
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4.2.2 Reagents and Treatments
AG205 was purchased from Timtec, Inc., (Newark, NJ). Dose response
and time courses were performed previously (data not shown) to establish the
most effective concentrations and times. A549 and HUH7 cells were treated with
AG205 (20 μM) for 90 minutes and underwent protein analysis or cell surface
labeling. A549 control and PGRMC1-knockdown were plated on glass bottom
microwell dishes (MatTek Corporation, Ashland, MA) for imaging. A549 control
and PGRMC1-knockdown were treated with recombinant human insulin, Cy5
labeled (Nanocs Inc., New York, NY) at a concentration of 100 nM for 5 minutes
and 15 minutes. Cells were visualized using a Nikon A1R+ resonant scanning
confocal system at the University of Kentucky Imaging Facility and analyzed with
NIS-Elements C imaging software.

4.2.3 Cell Surface Labeling Assays
For a single experiment, four dishes of 90-95% confluent cells were used.
After the removal of media, cells were washed twice with ice-cold phosphatebuffered saline (PBS) (VWR, Radnar, PA) and labeled with sulfo-NHS-SS-biotin
(sulfosuccinimidhyl-2(biotinamido)-ethyl-1,3-dithipropionate) for 30 minutes at
4°C on a rocking platform. The labeled proteins were purified with avidin agarose
using the Cell Surface Protein Isolation Kit (Thermo Scientific, Waltham, MA)
according to the manufacturer’s instructions. For comparison, the intracellular
protein pool that did not bind avidin-agarose was also collected and stored as the
“unbound” or “cytoplasmic” fraction. Cell surface labeling reactions were
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performed at least in triplicate and fraction levels were confirmed via SDS-PAGE
gel separation and staining with Coomassie Blue as previously described (23).
Western blots of biotin-labeled eluates and unbound fractions were performed at
least in triplicate.

4.2.4 Immunological Techniques
For western blot analysis, cell lysates were prepared by incubating cells in
RIPA buffer (50mM Tris-HCl [pH 7.4], 1% NP40, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 μg/mL
aprotinin, and 1 μg/mL leupeptin) for 10 minutes at 4°C. Lysates were cleared by
centrifugation at 14,000 x g for 10 minutes at 4°C, and proteins were separated
by gel electrophoresis. The antibodies used in this study were anti-insulin
receptor beta (Novus Biologicals, Littleton, CO) anti-insulin receptor β (Cell
Signaling, Danvers, MA), PGRMC1 (Abcam, Cambridge, MA), anti-proliferating
cell nuclear antigen (PCNA; PC-10, Santa Cruz Biotechnology, Santa Cruz, CA),
anti-GAPDH (Santa Cruz), anti-GLUT4 (Santa Cruz), anti-GLUT1 (Santa Cruz).
Western Blots for PGRMC1 were performed with the PGR-UK1 polyclonal antibody directed to the sequence QPAASGDSDDDE of the PGRMC1 coding
sequence (22). Western blots were performed at least in triplicate. For
immunoprecipitations, cells were gently scraped off dishes and lysed in Nonidet
P-40 buffer (1% Nonidet P-40, 20 mM Tris, 150 mM NaCl, 5 mM EDTA, 1 μg/mL
aprotinin, and 1 μg/mL leupeptin) for 10 minutes at 4°C. Lysates were cleared by
centrifugation at 14,000 x g for 10 minutes at 4°C, and bound to Protein A/G71

agarose beads (Santa Cruz) containing antibody. Nonspecific antibodies
matching the host species of the primary antibodies were included as negative
controls. The reactions were rotated end over end at 4°C for 1.5 hours,
centrifuged to collect precipitates, and washed 3 times in lysis buffer. The beads
were resuspended in 1x sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) sample loading buffer and analyzed via western
blot.

4.2.5 2-Deoxyglucose Uptake
For radioactive glucose uptake measurements, A549 control and
PGRMC1-knockdwon cells (5 x 105/well) were plated in separate 12-well plates
in serum containing medium (DMEM) overnight. Cells were then washed twice in
PBS, and incubated in RPMI-1640 media (VWR, Radnar, PA) containing 1%
BSA (VWR, Radnar, PA) for 2 hours before glucose uptake studies. Cells were
then washed twice with PBS and incubated in 1 ml PBS containing 0.1 mM
2-deoxyglucose and 1 μCi/ml 2-deoxy-D-[3H] glucose (Perkin Elmer, Boston,
MA) for 5 minutes at 37°C. Cytochalasin B (20 μM; Sigma Aldrich, St. Louis, MO)
was added to the relevant wells with the deoxyglucose mixture to serve as a
negative control. Then, cells were washed three times in ice-cold PBS,
solubilized in 0.4 ml of 1% SDS for 10 minutes at room temperature and was
counted in 4 mL of Biosafe II scintillation fluid (Research Products International
Corp., Mount Prospect, IL) for 1 minute on a Beckman LS6500 scintillation
counter.
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4.2.6 Statistics
Figures show representative blots and each experiment was performed at
least three times. Quantitation of bands was performed using Adobe Photoshop
software (Adobe Systems, San Jose, CA). Data are expressed as mean ±
standard deviation and were analyzed by using Student’s paired, two sided t test
to assess significance. All measurements were considered significant if P ≤ 0.05
(*); P ≤ 0.01 (**); P ≤ 0.001 (***).

4.3 Results

4.3.1 PGRMC1-mediates elevation of IR plasma membrane levels
To test the role of PGRMC1 in plasma membrane stability of IR, we
compared membrane levels of IR in control and PGRMC1-knockdown A549
human lung cancer cells. Extracellular proteins were biotinylated and purified
with avidin column chromatography and then analyzed by western blot using an
antibody to the IR β sub-unit. We will refer to IRβ as IR. IR levels decreased in
KD cells relative to controls (Figure 4.1A, compare lanes 3 and 4). IR was not
detectable in the cytoplasmic fraction (Figure 4.1A, compare lanes 1 and 2),
which was diluted relative to the membrane fraction. A coomassie brilliant bluestained gel of the fractions revealed few changes in band intensity (Figure 4.1B).
Verification of this protocol for precipitation of the cytoplasmic and plasma
membrane fractions in A549 cells has been previously reported (23). In multiple
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experiments, IR plasma membrane levels decreased 2.3-fold in PGRMC1knockdown cells relative to controls (p<0.005, t-test Figure 4.1C). In contrast,
depletion of PGRMC1 did not affect the total protein levels of IR (Figure 4.1D).
In lung cancer cells, PGRMC1 is inhibited by the ligand AG205 (23). To
examine pharmacological inhibition of PGRMC1 on IR plasma membrane
stability, we treated HUH7 human liver cancer cells, in addition to A549 human
lung cancer cells, with AG205. Cell surface proteins were labeled, purified and
analyzed by western blot as described above. Plasma membrane levels of IR
were profoundly reduced after treatment with AG205 in both cell lines (Figure
4.2A-B, compare lanes 3 and 4). The nuclear protein PCNA (proliferating cellular
nuclear antigen) served as a control for intracellular proteins (Figure 4.2A-B,
compare lanes 1 and 2) and Coomassie Blue-stained gel of the fractions showed
no variability in band intensity (Figure 4.2C-D). In multiple experiments, AG205
treatment decreased plasma membrane IR levels in both A549 and HUH7 cells
by 57.5-fold and 6.8-fold respectively (Figure 4.2G-H, p<0.005 and p<0.01
respectively). As before, total cellular protein levels of IR were not affected after
treatment with AG205 (Figure 4.2E-F). Together, these results suggest that
PGRMC1 inhibition via AG205 treatment also decreases plasma membrane
levels of IR. In these experiments, IR was detected in the unlabeled
“cytoplasmic” fraction. This differed from the control and PGRMC1-knockdown
cells in Figure 4.1. We speculate that the infection and selection process of the
cells in Figure 4.1 may have increased the fractions of IR present at the plasma
membrane.
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4.3.2 IR and PGRMC1 co-precipitate
PGRMC1 interacts directly with the EGFR receptor tyrosine kinase and
the [8 membrane spanning] receptor [MAPR1a], suggesting that the regulation of
IR by PGRMC1 could be direct. Both PGRMC1 and IR were immunoprecipitated from A549 lung cancer cells and HUH7 liver cancer cells and
analyzed by western blot. IR was efficiently precipitated (Figure 4.3A, upper
panel), and PGRMC1 co-precipitated with IR (Figure 4.3A, lower panel) in both
cell lines (lanes 2 and 4). Similarly, PGRMC1 was efficiently precipitated (Figure
4.3B, upper panel), and IR co-precipitated with PGRMC1 (Figure 4.3B, lower
panel) in both cell lines (lanes 2 and 4). The same lysates were precipitated with
a host specific antibody that matched to the antibodies for IR and PGRMC1
(Figure 4.3A-B, lanes 1 and 3). As an additional control, IR and PGRMC1 were
precipitated from A549 control and PGRMC1-knockdown cells, and PGRMC1
was only detected in control cells (Figure 4.3C, lane 2).

4.3.3 Cellular binding of insulin dependent on PGRMC1
Insulin is the most potent physiological agent known, and insulin’s
biological actions are direct results of the interaction with IR (186). To determine
the effect of PGRMC1 on insulin binding, A549 control and PGRMC1-knockdown
cells were incubated with insulin labeled with the fluorophore cyanine-5 (we will
refer to this as “Cy5-insulin”). Cy5-insulin bound readily to control A549 cells
(Figure 4.4C), while binding was largely undetectable in PGRMC1-knockdown
75

cells (Figure 4.4D). In the absence of Cy5-insulin, no fluorescence was observed
(Figure 4.4A-B). To better understand the pharmacodynamics of insulin binding,
A549 control and PGRMC1-knockdown cells were incubated with Cy5-labeled
insulin for a longer period of time (15 minutes) and real-time data was collected
via video recording on a Nikon A1R+ confocal microscope (video not attached).
At the end of the time-lapse, insulin binding was 10-fold higher in control cells
compared to PGRMC1-knockdown cells (Figure 4.4E). Thus, the results support
the model that PGRMC1 mediates the interaction of IR with its ligand, insulin.

4.3.4 PGRMC1 mediates Glucose Transporter Plasma Membrane Levels
and facilitates Glucose Uptake
IR stimulation causes the glucose transporter GLUT-4 to translocate from
intracellular vesicles to the plasma membrane (167, 187). Because PGRMC1
elevated IR plasma membrane levels, we posited that it would also increase
plasma membrane GLUT-4. Indeed, plasma membrane GLUT-4 levels declined
in PGRMC1-knockdown cells (Figure 4.5A, upper panel). Interestingly, the levels
of the constitutive glucose transporter, GLUT-1, also declined in PGRMC1knockdown cells, although to a lesser extent (Figure 4.5A, lower panel). In
triplicate experiments, the decreases in GLUT-4 and GLUT-1 in A549/RNAi cells
were 2.6-fold (p<0.01) and 1.5-fold (p=0.02), respectively (Figure 4.5B). The
total protein levels of GLUT-4 and GLUT-1 did not change between control and
PGRMC1-knockdown cells (Figure 4.5C).
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Because PGRMC1 increased the levels of glucose transporters at the
plasma membrane, we tested whether glucose transport was also affected. A549
control and PGRMC1-knockdown cells were incubated with 3H-glucose and
washed extensively. PGRMC1-knockdown cells exhibited a 1.5-fold decrease in
basal uptake of 3H-glucose compared to control cells (Figure 4.5D, p=0.0007, ttest). The actin polymerization inhibitor cytochalasin B, which arrests the
transport of glucose transporters to the plasma membrane, served as a negative
control.

4.4 Discussion
IR plays a crucial role in metabolism and performs key functions in the
muscle, fat and brain (188). IR is also over-expressed in cancer (189), where it
has a ligand-dependent transforming activity in fibroblasts (190). Cancer cells
typically express the IR-A form (191), which is also expressed in embryonic
tissues and in the brain, and differs from the IR-B isoform, which has an
additional 12 amino acids due to a splice variant in exon 11 (192, 193). IR-A acts
as a receptor for IGF-II, which is induced in cancer, with equal affinity to IGF-1R
(191), suggesting that IR directs tumor-specific signaling that promotes
metabolism.
The current work demonstrates a key role for PGRMC1 in maintaining IR
at the plasma membrane. We primarily used A549 cells because we have a
verified and well characterized RNAi-mediated knockdown model system in A549
cells (22, 23, 46). A549 cells express IR, and IR increases proliferation and
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therapeutic resistance in this non-small cell lung cancer cell line (163, 194, 195).
Our group previously showed that PGRMC1 is essential for trafficking the EGFR
receptor tyrosine kinase in cancer cells and is associated with EGFR (23). This
finding was elegantly extended by Kabe, et al., who showed that PGRMC1 forms
heme-dependent dimers that associate with EGFR, driving downstream
signaling, cell transformation and tumor metastasis (20). We report here that
PGRMC1 also associates with IR and increases IR plasma membrane levels.
Future research will determine whether PGRMC1 complexes with IR are also
heme-dependent.
PGRMC1 elevates the plasma membrane levels of two glucose
transporters and increases glucose transport (Figure 4.6). The most likely
mechanism of activated GLUT-4 plasma membrane levels is increased signaling
through IR, while extracellular GLUT-1 levels were elevated by PGRMC1 to a
lesser extent. Mammalian glucose transport is mediated by a family of membrane
glycoproteins, including GLUT-1 and GLUT-4 (196). The GLUT-1 isoform is
ubiquitously expressed and facilitates basal glucose uptake and transport across
blood tissue barriers, while the GLUT-4 isoform is predominately found in the
muscle, fat and heart tissues and mediates the rate-limiting step in regulated
transport in these tissues (197). There is evidence supporting an interaction
between GLUT-1 and GLUT-4 in insulin sensitive tissues, where GLUT-1 is
localized to the plasma membrane and GLUT-4 is distributed in intracellular
compartments until insulin signaling initiates the translocation of GLUT-4 to the
plasma membrane (198). The concentration of GLUT-4 at the cell surface and

78

duration for which the protein is maintained at the surface governs the rate of
glucose transport into fat and muscle cells (199). We note that EGFR has been
reported to associate with the sodium/glucose co-transporter SGLT-1 in a kinaseindependent manner (200), and glucose transport could be affected via PGRMC1
through this interaction. There is also evidence for cross-talk between IR and
EGFR in the A549 cell line (163). Finally, we cannot exclude the possibility that
PGRMC1 interacts directly with the glucose transporters, particularly GLUT-1.
The findings are consistent with our earlier observation that PGRMC1
decreases AMPK threonine 174 phosphorylation (138), an activating
phosphorylation event. AMPK activation increases glucose transport and
decreases competing pathways in energy metabolism (201, 202). Thus, AMPK
activation in PGRMC1-depleted cells may be a consequence of the depleted
glucose transport detected in the present study. However, AMPK is also capable
of directing GLUT-4 trafficking to the plasma membrane (202), suggesting that, in
addition to stabilizing IR plasma membrane pools, PGRMC1 may also play a
more direct role in regulating glucose transporters.
The pathways controlling IR plasma membrane trafficking are less well
characterized than some other receptors, such as EGFR. However, key proteins
include LMBD1/limb region domain containing 1 (203), PKC/protein kinase C
(204) and the adaptor protein GRB10/growth factor receptor bound protein 10
(177, 205). IR is ubiquitinated and associates with the ubiquitin ligase NEDD4
via GRB10 and with the E3 ubiquitin ligase mitsugumin 53 (206) and
APS/adaptor protein with pleckstrin homology and Src homology 2
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domains/SH2B adaptor protein 2 (207). This group of proteins affect the
internalization and degradation of IR, likely with variations between the two IR
isoforms, in different tissues and with different types of ligand stimulation (177).
An important future direction of the research will be to identify PGRMC1interacting partners in regulating IR trafficking.
In these experiments, the PGRMC1 ligand AG205 decreased the levels of
IR at the plasma membrane without affecting overall IR protein concentrations.
AG205 appears to act as an inhibitor of PGRMC1 in cancer cell lines, because
AG205 and PGRMC1 inhibition by RNA interference had a similar effect on
proliferation (22), NGAL/neutrophil gelatinase-associated lipocalin secretion (46)
and autophagy induction (138). AG205 acts to a significant extent through
PGRMC1, because PGRMC1-knockdown cells fail to arrest in response to
AG205 (22). The current findings indicate that AG205 treatment causes distinct
effects on protein stability in cancer cells, because EGFR levels were decreased
at the doses used here (23), while IR was unaffected. The underlying
mechanism through which AG205 and PGRMC1 affect protein stability is
unclear.
These results presented here indicate a novel mechanism through which
IR is trafficked by PGRMC1 (Figure 4.6). Several studies have shown that the IR
pathway is directly involved in cancer progression and development, suggesting
that this is an important new target for cancer prevention and therapy. We have
found that PGRMC1 directly associates with IR, maintains IR at the plasma
membrane and increases insulin binding and glucose uptake in cancer cells
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(Figure 4.6). Both genetic manipulation and the PGRMC1 inhibitor AG205
altered IR at the plasma membrane in cell lines from different tissue types.
A future direction of the research will be to determine the systemic activity of
AG205 and other potential PGRMC1 ligands. In prior in vivo experiments in our
laboratory, effects on glucose levels were not determined and studies of efficacy
were limited by the quantity of the drug that could be obtained. However, the
present studies suggest that PGRMC1 may be an important metabolic regulator
with the potential to target signaling in cancer.
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Figure 4.1 PGRMC1 increases IR plasma membrane levels. (A) Western blot
analysis of plasma membrane (PM) protein levels from control (“con”, lanes 1-2)
and PGRMC1-knockdown cells (“KD”, lanes 3-4) labeled with biotin and purified
by avidin-agarose. Proteins that were not detected at the plasma membrane are
indicative of cytoplasmic (cyto) proteins (lanes 1-2). The experiment was
performed five separate times. (B) Coomassie-stained gel of the samples
represent total protein levels. (C) Graphical representation of IR plasma
membrane levels reduced in knockdown (KD) vs control (con) cells (p<0.001).
(D) Western blot example of total IR protein levels in control and knockdown
cells. ***, p<0.001, compared with the vehicle-treated group.
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Figure 4.2 Treatment with PGRMC1 ligand AG205 decreases IR plasma
membrane levels. (Figure legend on following page)
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Figure 4.2 Treatment with PGRMC1 ligand AG205 decreases IR plasma
membrane levels. Western blot analysis of plasma membrane (PM) protein
levels in A549 (A) and HUH7 (B) cell lines from control (lanes 1-2) and AG205
(20 μM) treated (lanes 3-4 respectively) labeled with biotin and purified by avidin
agarose. Proteins that were not detected at the plasma membrane are indicative
of cytoplasmic (cyto) proteins (lanes 1-2). PCNA serves as a control for
intracellular proteins. Coomassie Blue-stained gel represents total protein levels
in A549 (C) and HUH7 (D) cell lines respectively. (E-F) Western blot analysis of
total IR protein levels in A549 cells and HUH7 cells -/+ AG205 treatment. IR
plasma membrane levels were significantly reduced after treatment with AG205
in both A549 (G) and HUH7 (H) cells (p<0.001 and p<0.01 respectively). **,
p<0.01; ***, p<0.001 compared with the vehicle-treated group.
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Figure 4.3 IR co-precipitates with PGRMC1. (A) IR and (B) PGRMC1 were
immunoprecipitated from A549 cells (lanes 1 and 2) and HUH7 cells (lanes 3 and
4) and probed (western blot analysis) for IR (top) or PGRMC1 (bottom). (C) IR
(top panel) and PGMC1 (bottom panel) were immunoprecipitated from control
(lane 1) or PGRMC1-knockdown (“KD”, lane 2) cells. Immunoprecipitation
reactions were probed for PGRMC1 (top and bottom panels).
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Figure 4.4 Cellular binding of insulin is dependent on PGRMC1. (Figure
legend on following page)
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Figure 4.4 Cellular binding of insulin dependent on PGRMC1. To visualize
insulin binding, control (“con”) and PGRMC1-knockdown (“KD”) A549 cells were
incubated with Cy5-labeled insulin (100 nM) and imaged. (A-B) Control and
PGRMC1-knockdown cells before insulin treatment (“untr”) and (C-D) 5 minutes
after the addition of Cy5-labeled insulin. Fluorescence revealed a reduction of
insulin binding in PGRMC1-knockdown cells. Images are representative of
experiments performed in triplicate. (E) In a separate experiment, control and
PGRMC1-knockdown cells were incubated with Cy5-labeled insulin (100 nM) for
15 minutes. The insulin binding was recorded live (videos in supplemental figure
1) and the NIS-Elements C imaging software data was exported to excel. Insulin
binding was significantly lower in PGRMC1-knockdown cells (p<0.001, t-test).
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Figure 4.5 PGRMC1 increases glucose uptake. (A) Western blot analysis of
plasma membrane (PM) protein levels from control (“con”) and PGRMC1knockdown cells (“KD”, lanes 2 and 4) labeled with biotin and purified by avidin
agarose. (B) Graphical representation of reduced GLUT-4 and GLUT-1 levels at
the plasma membrane in PGRMC1-knockdown cells (p<0.01 and p<0.05). (C)
Western blot analysis of total GLUT-1 and GLUT-4 levels did not change in
control vs knockdown cells. (D) Radioactive glucose uptake assay in control and
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PGRMC1-knockdown cells. Knockdown of PGRMC1 significantly reduced the
uptake of 3H-glucose in A549 cells (p<0.001). Cytochalasin B served as a
negative control (inhibits glucose transport). *, p<0.05; **, p<0.01; ***, p<0.001
compared with the vehicle-treated group.
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Figure 4.6 PGRMC1 trafficks IR to the plasma membrane and promotes
glucose entry. Schematic representation for the model in which PGRMC1
associates with IR to increase IR levels at the plasma membrane. IR at the
plasma membrane is capable of initiating the signaling cascade to translocate
glucose transporters from GLUT containing vesicles to the plasma membrane for
glucose entry. Red arrows represent events mediated by PGRMC1.
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5.1 Introduction
Rates of diabetes are expected to increase due to rampant obesity and
will become a worldwide health crisis in the future (208). The manifestations
include hypertension, hyperlipidemia, hyperglucocorticoidemia and type 2
diabetes. The latter is associated with insulin resistance, a heterogeneous
disease characterized by defects in insulin signaling (209). The insulin receptor
(IR) is a receptor tyrosine kinase that initiates the process, and IR signaling is
coordinated through multiple cascades (210). Binding of insulin to its receptor
(IR) triggers downstream signaling that includes IRS1/2 (insulin receptor
substrate), AKT and ERK (174). IR is a tetramer comprised of 2 alpha (ligand
binding) and 2 beta (kinase domain) chains that is expressed in numerous
tissues. Signaling from the IR through the IRS-1/PI3K/AKT pathway results in a
rapid translocation of the GLUT-4 glucose transporter from intracellular vesicles
to the plasma membrane, increasing the cellular uptake of glucose (175), a step
that is critical in preventing diabetes complications.
Adipose tissue performs a key function in glucose homeostasis, because it
acts as a reservoir for circulating glucose, converting the sugar into lipid for
storage (211). When there is an excess of adipose tissue, such as in high BMI
individuals, the glucose catabolism is disrupted, and diminished insulin receptor
function is thought to contribute (212). Indeed, obese individuals show
decreased insulin binding in skeletal muscle, adipose tissue and liver (50).
Mouse models of skeletal-muscle specific vs fat-specific IR-knockout (MIRKO
and FIRKO accordingly) suggest that glucose uptake by muscle is more
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significant for diabetes, which was anticipated since the muscle is believed to
account for 80% of glucose disposal (210, 213). However, other studies suggest
that adipose is a critical site for glucose metabolism and the development of
obesity and its associated abnormalities (214).
PGRMC1 (progesterone receptor membrane component 1) plays an
important role in signaling by transporting transmembrane receptors to the
plasma membrane, including receptor tyrosine kinases (1, 26, 47, 178).
PGRMC1 localizes to endosomes, the endoplasmic reticulum and the plasma
membrane, the latter being consistent with its highly conserved role in trafficking
(23, 27, 86). In cancer, PGRMC1 associates with the EGFR (epidermal growth
factor receptor) tyrosine kinase (20, 23, 45, 46), increases plasma levels of
EGFR, and increases cellular signaling (22, 23, 28, 90). In contrast, the EGFRrelated protein HER2/neu was not PGRMC1-dependent (23), suggesting a
trafficking specificity.
In addition to tyrosine kinases, PGRMC1 also increases plasma
membrane pools of GLP-1R and the plasma membrane progesterone receptor,
MPRα1 (26, 47). The latter likely contributes to progesterone binding activity by
the PGRMC1 complex, which was how PGRMC1 was originally identified (3, 4,
10, 83). Binding to the liganded GLP-1R complex likely contributes to glucose
homeostasis, as PGRMC1 has been found to modulate glucose-induced insulin
stimulation in beta cells (47). PGRMC1 has numerous other binding partners,
including cytochrome P450 proteins, PAIR-BP1 (plasminogen activator inhibitor
RNA binding protein 1) and α-tubulin (30). PGRMC1 is an appealing therapeutic
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target because it has a small molecule ligand, called AG205 (22), that was
identified by our group and has been verified by others (22, 82). Based on
photoaffinity cross-linking studies with a labelled sigma-2 receptor ligand called
WC-21, PGRMC1 was identified as the sigma-2 receptor (82). Sigma receptors
are low molecular weight receptors for multiple endogenous and exogenous
ligands (96). It is notable that PGRMC1 was originally thought to be a sigma
receptor (83).
In the present study, we have investigated the role of PGRMC1 in adipose
specific IR regulation. There is a precedent for PGRMC1 being associated with
insulin signaling, because a clinical study of insulin-resistant, high BMI subjects
demonstrated decreased PGRMC1 RNA levels compared to insulin-sensitive
subjects (185). However, this study did not provide a direct link between IR and
PGRMC1. Based on previous findings by our group that PGRMC1 regulated
receptor tyrosine kinase trafficking via direct binding, we posited that PGRMC1
binds to IR. Furthermore, in adipose tissue from high BMI patients, a small
molecule PGRMC1-directed therapeutic increased levels of IR. This is the first
report of increased IR protein levels in high BMI patients through
pharmacological intervention. The findings suggest that PGRMC1 is important for
signaling though the IR and may play an important role in diabetes.
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5.2 Material and methods

5.2.1 Human samples
Human tissue samples were from the lab of Dr. Phil Kern. Biopsies from
abdominal subcutaneous adipose tissue were obtained from nondiabetic subjects
that were deidentified and only paired with their respective BMI. Tissue samples
were immediately placed on ice and stored at -80°C until analysis. After thawing,
tissue samples were lysed in 1mL cold RIPA buffer (50mM Tris-HCl [pH 7.4], 1%
NP40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 1 μg/mL aprotinin, and 1 μg/mL leupeptin) via
pipetting and sonication (30 seconds). After a 5 minute incubation at 4°C,
samples were cleared at 1,000 x g. The infranatant was collected and cleared at
1,000 x g for an additional 5 minutes at 4°C. Protein quantification was
performed using the Pierce BCA Protein Assay kit (Thermo Fischer Scientific,
Waltham, MA).

5.2.2 Cell Culture
Fully differentiated human subcutaneous adipocytes from multiple donors
were purchased from Zenbio, Inc., (Research Triangle Park, NC) and maintained
in proprietary media according to the manufacturer’s instructions. Lot#SL0055
contained differentiated human subcutaneous adipocytes derived from 10 female
donors with a median age of 46.7 and median BMI of 26.8. Lot #L100610B
contained differentiated human subcutaneous adipocytes from a female
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Caucasian with a BMI of 23.3 and age of 40. Lot#L072709 contained
differentiated human subcutaneous adipocytes from a female of unknown
ethnicity with a BMI of 38.0 and age of 39. All donors were listed as nonsmokers.
3T3-L1 cells were obtained from ATCC (Manassas, VA), verified by
Genetica LLC (Cincinnati, OH) and cultured under the suggested conditions
according to ATCC. 3T3-L1 cells were maintained in media purchased from
Zenbio, Inc., (Research Triangle Park, NC) and differentiated according to
manufacturer’s protocol. Medium included: Preadipocyte Medium (cat# PM-1L1), Differentiation Medium (cat# DM-2-1) and Adipocyte Medium (cat# AM-1L1).
The collection of stromal vascular fraction was obtained from the visceral
fat of male, Sprague-Dawley rats (Taconic Biosciences, Hudson, NY) after CO2
asphyxiation. Harvested fat was washed in ice-cold HBSS (VWR, Radnar, PA),
finely minced, and digested in 1 mg/ml type II collagenase solution prepared in
HBSS (Sigma Aldrich, St. Louis, MO) for 45 min at 37°C with vigorous shaking.
The mixture was then filtered through 250 μM gauze mesh into a 50 mL tube and
let stand 2-3 minutes. Infranatant containing the collagenase solution was
removed, and the floating layer of adipocytes were washed 3x with 10 mL
phosphate-buffered saline (VWR, Radnar, PA). The adipocytes were incubated
with collagenase II solution (2mL), vortexed and left shaking for 10 minutes at
37°C. After incubation, 2 mL of high-glucose DMEM (Corning, Manassas, VA)
containing 10% BCS (Sigma Aldrich, St. Louis, MO) was added, mixed and the
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solution was filtered through 70 μM nylon mesh cell strainer (VWR, Radnar, PA)
and plated for cell culture. After cells were approximately 100% confluent, cells
were differentiated according to the Zenbio, Inc., manufacturer’s protocol
(Research Triangle Park, NC).

5.2.3 Reagents and Treatments
AG205 was purchased from Timtec, Inc., (Newark, NJ) and PB28 was
purchased from Sigma Aldrich (St. Louis, MO). Differentiated human
subcutaneous adipocytes were treated with the PGRMC1 ligands, AG205 (10μM)
and PB28 (1μM), for 24 hours and analyzed via western blot. Dose response
and time courses were performed previously (data not shown) to establish the
most effective concentrations and times. Differentiated 3T3-L1 cells and
differentiated rat SVF-isolated cells were incubated with AG205 (20uM) for 90
minutes and underwent protein analysis.

5.2.4 Immunological Techniques
For western blot analysis, cell lysates were prepared by incubating cells in
RIPA buffer (50mM Tris-HCl [pH 7.4], 1% NP40, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 μg/mL
aprotinin, and 1 μg/mL leupeptin) for 10 minutes at 4°C. Lysates were cleared by
centrifugation at 14,000 x g for 10 minutes at 4°C, and proteins were separated
by gel electrophoresis. The antibodies used in this study were anti-insulin
receptor beta (Novus Biologicals, Littleton, CO) anti-insulin receptor β (Cell
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Signaling, Danvers, MA), PGRMC1 (Abcam, Cambridge, MA), and anti-GAPDH
(Santa Cruz). Western Blots for PGRMC1 were performed with the PGR-UK1
polyclonal anti-body directed to the sequence QPAASGDSDDDE of the
PGRMC1 coding sequence (22). Western blots were performed at least in
triplicate.
For immunoprecipitations, cells were gently scraped off dishes and lysed
in Nonidet P-40 buffer (1% Nonidet P-40, 20 mM Tris, 150 mM NaCl, 5 mM
EDTA, 1 μg/mL aprotinin, and 1 μg/mL leupeptin) for 10 minutes at 4°C. Lysates
were cleared by centrifugation at 14,000 x g for 10 minutes at 4°C, and bound to
Protein A/G-agarose beads (Santa Cruz) containing antibody. Nonspecific
antibodies matching the host species of the primary antibodies were included as
negative controls. The reactions were rotated end over end at 4°C for 1.5 hours,
centrifuged to collect precipitates, and washed 3 times in lysis buffer. The beads
were resuspended in 1x sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) sample loading buffer and analyzed via western
blot. The antibodies used in this study were anti-insulin receptor (Novus
Biologicals, Littleton, CO), anti-insulin receptor β (Cell Signaling, Danvers, MA),
PGRMC1 (Abcam, Cambridge, MA), anti-GAPDH (Santa Cruz).
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5.3 Results

5.3.1 IR regulation in human differentiated adipocytes
The down-regulation of PGRMC1 in insulin-resistant diabetes suggest a
role for PGRMC1 in regulating IR in adipocytes. To test this model, human
tissue-derived adipocytes were treated with PGRMC1 ligand AG205 (22).
PGRMC1 has been identified as the sigma-2 receptor in binding studies (82), so
we also tested the activity of the sigma-2 receptor ligand PB28 (215). The
cellular morphology of the adipocytes was unchanged upon treatment with either
ligand. AG205 significantly increased IRβ protein levels in adipocytes derived
from pooled BMI (body-mass index, median 26.8, range of [25.3-28.6]) donors
(Figure 5.1A-B, p=0.004, t-test) and the high BMI donor (BMI 38, p=0.013, t-test).
Treatment with PB28 increased IRβ protein levels in adipocytes derived from
both pooled BMI donors and the high BMI donor, but only adipocytes derived
from pooled BMI donors achieved statistical significance (Figure 5.1A-B,
p=0.027, t-test). There was no significant change in IRβ protein levels after
ligand treatments in adipocytes derived from the low BMI 23 donor. Protein
analysis was performed by western blot using an antibody to the IR β sub-unit.
Total basal IRβ protein levels were lower in adipocytes derived from pooled BMI
donors and the high BMI donor (Figure 5.1A-B, p=0.001 and 0.006, respectively,
t-test), indicative of reduced insulin sensitivity. In adipose tissue from subjects
with varying BMI, both IR and PGRMC1 protein levels decreased in subjects with
high BMI (Figure 5.2), consistent with RNA levels detected by microarray.
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5.3.2 IR regulation in rodent model systems
Although human tissue-derived adipocytes are a highly accurate model
system for studying human metabolic processes, they vary between individuals
and populations. In order to further characterize the interaction of PGRMC1 with
IR, we utilized two rodent model systems-the 3T3-L1 murine cell line and cells
isolated from stromal vascular fractions derived from the subcutaneous adipose
of Sprague Dawley rats. To determine the effect of the PGRMC1 ligands on IR
levels in these rodent model systems, we treated differentiated 3T3-L1 cells and
differentiated rat SVF-isolated cells with AG205. Interestingly, the drug treatment
significantly reduced total IR protein levels in both rodent model systems (Figure
5.3A-B, lanes 2. p<0.05 and p<0.01 respectively). These results were opposite of
the pharmacological effects seen in human adipocytes.
Next, we investigated the potential interaction of PGRMC1 with IR.
PGRMC1 interacts directly with the EGFR receptor tyrosine kinase and the [8
membrane spanning] receptor mPRα. Furthermore, we have detected a direct
interaction between PGRMC1 and IR in human cancer cells (data in press). Both
PGRMC1 and IR were immuno-precipitated from differentiated 3T3-L1 cells and
analyzed by western blot. IRβ was efficiently precipitated (Figure 5.3C, upper
panel lane 2), and PGRMC1 co-precipitated with IRβ (Figure 5.3C, lower panel
lane 2). Similarly, PGRMC1 was efficiently precipitated (Figure 5.3D, upper panel
lane 2), and IRβ co-precipitated with PGRMC1 (Figure 5.3D, lower panel lane 2).
The same lysates were precipitated with a host specific antibody that matched to
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the antibodies for IRβ and PGRMC1 (Figure 5.3C-D, lanes 1). These results
suggest a direct interaction of PGRMC1 with IR.

5.4 Discussion
IR signaling is key in the progression of metabolic disease, and we have
shown that IR levels are elevated in adipocytes treated with two different ligands
for the PGRMC1 protein. This stands in stark contrast to the behavior of the
PGRMC1 ligand AG205 in cancer cells, where it has no effect on overall IR
levels (Hampton and Craven, in review) and decreases EGFR levels (23).
Despite multiple sources confirming the identity between PGRMC1 and sigma-2
receptor (82, 216, 217), the co-identity of the two proteins is controversial (160,
218, 219). In a set of pooled adipocytes from 10 donors, AG205 and PB28
behaved similarly, but the trend of IR elevation by PB28 in a high BMI donor did
not achieve significance.
Notably, the finding that AG205 increased IR levels in human adipocytes
was not extended to two different widely used model systems for obesity- mouse
3T3-L1 cells and adipocytes from Sprague-Dawley rats. The results suggest an
intriguing species-specific function for PGRMC1 in fat. Nagy and colleagues
recently reviewed the physiological and metabolic profiles of rodent white
adipose fat pads with white adipose fat depots in humans and urged researchers
to carefully consider experimental designs given some of the stark differences in
adipose tissue location and function among species (220). Furthermore, Barnard
and colleagues argued dietary modification in rodent models has limited
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translatable benefit for understanding the pathogenesis of human obesity and
diabetes based on the constraints of HFD (high-fat diet) (221).
Finally, Elbein et al, showed that PGRMC1 RNA levels decrease in
adipose tissue from insulin-resistant subjects compared to insulin-sensitive
subjects (185). Our findings extend the observation in a small cohort of adipose
tissues, revealing diminished PGRMC1 protein levels in two high BMI subjects.
Thus, there is potentially a strong translational impact because the research will
develop new small molecule therapeutics that will potentially enhance the
treatment of insulin-sensitive diabetes and reverse the course of insulin-resistant
diabetes. The overall impact of the study could be profound. With millions of
people worldwide expecting to develop diabetes in the future, PGRMC1-directed
therapeutics could become an important approach to treating the disease. There
are a number of diabetes treatments currently available, including drugs that
lower blood sugar (222), activate IR and alter the production of insulin. Because
of the long-term course of the disease and the vast numbers of people becoming
diabetic, however, new therapeutics are needed for diabetes.
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Figure 5.1 PGRMC1 ligand treatment in human adipocytes. Insulin Receptor
β (IRβ) levels increase significantly after 24 hour treatment with 10μM AG205
and 1μM PB28 in human subcutaneous cultured adipocytes. (A) Western blot
analysis of human subcutaneous adipocytes derived from 10 separate donors.
GAPDH served as a loading control. (B) IRβ protein levels were determined by
western blot in fully differentiated human adipocytes sourced from multiple
donors with a median BMI of 26.8 (Pooled), a donor with a 23 BMI (Low BMI),
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and donor with a 38 BMI (High BMI). IRβ protein levels were significantly
elevated after treatment with AG205 and PB28 (p=0.004 and p=0.027
respectively) in pooled BMI adipocytes. Treatment with AG205 significantly
increased IRβ levels in adipocytes derived from a high BMI donor (p=0.013).
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Figure 5.2 PGRMC1 decreases with glucose insensitivity in human adipose
tissue. Adipose tissue samples biopsied from human patients matched with BMI.
Protein analysis via western blot show a reduction of both PGRMC1 and IRβ
levels with increasing BMI.
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Figure 5.3 PGRMC1 ligand treatment and co-immunoprecipitation with IR in
rodent model systems. Western blot analysis of total IRβ protein levels in
differentiated 3T3-L1 cells and differentiated rat SVF-isolated cells after AG205
(20μM) treatment. Total IRβ protein levels were significantly reduced after
treatment with AG205 (lane 2) in both differentiated 3T3-L1 (A) and rat SVFisolated (B) cells (p<0.05 and p<0.01 respectively). (C) IRβ and (D) PGRMC1
were immunoprecipitated (IP) from differentiated 3T3-L1 cells.
Immunoprecipitation with an irrelevant antibody (con Ab, lane 1) is a control. (C)
IRβ was immunoprecipitated (lane 2) and probed (western-blot) for IRβ (top
panel) and PGRMC1 (bottom panel). (D) PGRMC1 was immunoprecipitated
(lane 2) and probed for IRβ (top panel) and PGRMC1 (bottom panel).
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CHAPTER VI: DISCUSSION
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6.1 Summary of findings
Cancer is one of the leading causes of death, and the number of
worldwide cases are expected to increase approximately 50% over the next 20
years, with the numbers rising from 14 million cases in 2012 to 21 million cases
in 2030 (World Health Organization). PGRMC1 is a cytochrome b5 related
protein that is induced in a number of cancer types and is involved in tumor
formation, invasion and metastasis. Prior research in the field has primarily
focused on the role of PGRMC1 in breast, ovarian and lung cancer, and have
correlated PGRMC1 expression with tumor progression and stage. Typical
analyses include the use of cancer cell lines and clinical tumor samples.
Certainly, such studies provide valuable information, however, there remains a
need in the field to incorporate additional clinical samples, not limited to tumor
samples.
Herein, we have analyzed PGRMC1 levels in over 600 tumor sections,
including a larger cohort of lung tumors than in previous studies, and we report
the first clinical analysis of PGRMC1 levels in human oral cavity and ovarian
tumors compared to nonmalignant tissues. In lung and ovarian cancers,
PGRMC1 was highly elevated and correlated with patient survival. In addition to
clinical tumor samples, we report the first implication for PGRMC1 in cancer stem
cells. PGRMC1 was detected in lung-tumor derived stem cells isolated from in
the Appalachian population. More importantly, we report a essential role for
PGRMC1 in cancer stem cell viability. Drug treatment with the PGRMC1 small
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molecule, AG205, triggered stem cell death, while a chemotherapeutic and ERK
inhibitor, erlotinib and PD98059, did not.
There are a number of potential mechanisms in which PGRMC1 might
promote tumor growth, including its association with the epidermal growth factor
receptor (EGFR). EGFR is over-expressed in a large number of tumors and is
activated through changes in expression or mutations. Multiple drugs have been
developed to inhibit EGFR, including chimeric antibodies targeting the
extracellular domain and small molecule kinase inhibitors. The active kinase
domain inhibitors are particularly active against mutant forms of the receptor, and
subsequent mutations drive resistance to the inhibitors. This dissertation
includes a review focusing on the trafficking of wild-type and mutant EGFR, and
in doing so, found PGRMC1 inhibitors to be most active against the wild-type
form in EGFR-dependent cancer cell proliferation.
Although the number of cancer cases can be appreciated, the number of
diabetes cases worldwide overwhelmingly surpass cancer. In 2014, the World
Health Organization reported 422 million people in the world living with diabetes.
The widespread epidemic of obesity and type 2 diabetes has raised great
concern for the impact of these disorders in cancer development, with a major
concern being circulating insulin (223). Multiple studies have shown that the
insulin receptor (IR) pathway is directly involved in cancer development and
progression, and insulin is suggested to affect cancer growth (164). Like EGFR,
IR is a member of the receptor tyrosine kinase family.
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Analogous to our extensive data on the regulation of EGFR trafficking, we
demonstrate a role for PGRMC1 in the trafficking of IR. PGRMC1 co-precipitates
with IR and increases plasma membrane IR levels in multiple cancer cell lines.
Insulin binding to IR initiates a rapid translocation of glucose transporters to the
plasma membrane for glucose entry. Indeed, PGRMC1 also increases the
plasma membrane levels of two glucose transporters, GLUT-4 and GLUT-1, and
is essential for both glucose uptake and insulin binding. Taken together, our data
support a role for PGRMC1 in promoting insulin binding and glucose uptake at
least in part by binding IR and maintaining plasma membrane pools of the
receptor.
Insulin signaling regulates many crucial aspects of cellular physiology, and
the significance of our findings extend beyond the scope of cancer. Our goal is
to explore the interaction of PGRMC1 and IR in multiple physiological settings,
including the main organ linked with many disease states: adipose. Impaired
insulin signaling is central in the development of type 2 diabetes, and obese
individuals demonstrate decreased insulin binding due to a reduction of IR levels,
without an alteration in ligand-receptor affinity (50). We obtained fully
differentiated human subcutaneous adipocytes from donors ranging from low to
high BMIs and treated them with PGRMC1 ligands. We show treatment with
PGRMC1 ligands significantly increase IR protein levels in adipocytes derived
from high BMI patients. Protein levels appear to be affected through the direct
interaction of PGRMC1 and IR, as we demonstrate their co-precipitation in
another adipose model system, differentiated 3T3-L1 cells. These findings are
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remarkable; pharmacological treatment with PGRMC1 ligands restored IR levels
derived from high BMI adipocytes to mimic IR levels derived from low BMI
adipocytes.

6.2 Significance
This dissertation represents a significant advancement in understanding
the implication for PGRMC1 in disease states. Previous research has focused
on the role of PGRMC1 in membrane trafficking and cancer pathology, with an
emphasis on EGFR. However, as new research provides alternative
mechanisms and insights into disease pathology, the field of PGRMC1 must
evolve accordingly.

6.2.1 The relationship between PGRMC1 and wild-type EGFR
Mutations in the EGFR tyrosine kinase domain often result in increased
malignant cell survival, proliferation and metastasis (224). The discovery of
mutations in EGFR has resulted in the development of many anticancer drugs
that have provided a successful avenue for the treatment of certain cancers.
However, subsequent mutations in the receptor can lead to drug resistance and
only a subset of cancers contain EGFR mutations. Therefore tumors expressing
wild-type EGFR are often harder to treat.
To address these concerns, we summarized multiple signaling associated
pathways that are important in trafficking wild-type and mutant EGFR.
Furthermore, we found PGRMC1 to associate with wild-type EGFR 2.4-fold more
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than a mutant EGFR, and a PGRMC1 inhibitor was active against cells
expressing wild-type EGFR. These data indicate PGRMC1 as an attractive
target in the inhibition of wild-type EGFR-dependent cancer cell proliferation.

6.2.2 PGRMC1 as a potential biomarker and therapeutic target for cancer
stem cells
In the field of cancer research and care, the development of valid
biomarkers can provide useful information in guiding clinical decision making and
is becoming increasingly more important in the clinical management of cancer
patients (225). Accordingly, The Precision Medicine Initiative pledged $70 million
to the National Cancer Institute (NCI) in 2015, to “scale up efforts to identify
genomic drivers in cancer and apply that knowledge in the development of more
effective approaches to cancer treatment” (225).
In Chapter III, we include an analysis of PGRMC1 levels in over 600 tumor
sections. PGRMC1 was significantly elevated in a large cohort of tumors derived
from cancers of the airway, including the head and neck region. In lung cancer
samples, PGRMC1 was significantly higher in stage I tumors compared to stage
II tumors and correlated with patient survival. Furthermore, we report the first
analysis of PGRMC1 expression in a large cohort of ovarian cancer and found
high PGRMC1-expressing tumors to correlate with poor overall survival. These
data implicate PGRMC1 as a potential biomarker in a broad range of tumor
types.
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PGRMC1 has been previously associated with drug resistance, a
characteristic of cancer stem cells. The stem cell theory proposes that a subset
of cancerous stem cells contribute to drug resistance and tumor maintenance.
Therefore, in order to develop efficient treatments that can induce a long-lasting
clinical response, cancerous stem cells must be considered in drug development.
The association between PGRMC1 levels and tumors suggested a potential role
for PGRMC1 in stem cell maintenance, and we report the first evidence detecting
PGRMC1 expression in cancer stem cells. Remarkably, the PGRMC1 small
molecule, AG205, also induced stem cell death, whereas the powerful agents
(erlotinib and PD98059) did not.

6.2.3 The insulin receptor is proposed as a new target for cancer therapy
The identification of the mechanism(s) of insulin signaling in cancer
development and progression may represent an important factor in the
resistance to various anticancer drugs, particularly surrounding the dysregulation
of the insulin receptor (IR) (164). Malignant cells have been reported to
overexpress IRs that may reach or exceed expression levels physiologically
observed in insulin target organs, such as adipose tissue or the liver (223). The
insulin receptor consists of two isoforms, IR-A and IR-B, with the latter being
predominant in most adult and differentiated tissues (164). Furthermore, IR-B is
associated with metabolic and differentiating signaling, whereas IR-A mainly
favors cell growth, proliferation and survival. Indeed, the IR-A isoform is
predominantly expressed in cancer cells, and some studies suggest IR-A to be
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involved in cancer stem cell biology (164). The characterization of insulin
receptor trafficking has the potential to enhance our understanding of cancer
development and progression while simultaneously generating new therapeutic
targets.
Our data demonstrate that PGRMC1 associates with IR and trafficks IR to
the plasma membrane in multiple cancer cell lines. Furthermore, insulin binding
and glucose uptake were dependent on PGRMC1. Insulin has been known to
have mitogenic properties; circulating insulin affects cancer growth and
hyperinsulinemia is a major cancer risk factor for obese and diabetic patients
(223, 226). Additionally, elevated blood glucose levels have been hypothesized
to increase cancer risk and death in diabetic patients (226). Based on our
findings, PGRMC1 may be an important regulator in insulin driven cancer
development. Future studies involving the different IR isoforms may identify
mechanisms and therapeutics to target the IR-A pathway in order to inhibit the
tumor promoting effect of IR without impairing its metabolic effects.

6.2.4 Regulation of insulin receptor levels in human adipocytes derived
from a high BMI donor
According to the Centers for Disease Control and Prevention (CDC), more
than 1/3rd of the U.S. population is obese (36.5%). Adipocytes are one of the
most highly insulin-responsive cell types in the body, and insulin is a critical
regulator of adipocyte biology (227). Insulin signaling initiates at one central
point, the insulin receptor (IR), to stimulate glucose transport, promotion of
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adipocyte triglycerides storage, and uptake of fatty acids (210, 227). Chronic
exposure to insulin leads to a down-regulation of insulin signaling via reduced
insulin receptor expression at the plasma membrane, and obese individuals
demonstrate a reduction in IR abundance in adipose tissue (50, 228).
We report a novel regulator for IR levels in human and rodent adipocytes.
We show treatment with PGRMC1 ligands significantly increased total IR protein
levels in fully differentiated human subcutaneous adipocytes. More specifically,
IR levels in adipocytes derived from a donor with a high BMI were restored to
levels comparable to adipocytes derived from a donor with a low BMI. Protein
levels appear to be affected through the direct interaction of PGRMC1 and IR, as
we demonstrate their co-immunoprecipitation in differentiated 3T3-L1 cells. This
further validates our data in cancer cells demonstrating the role of PGRMC1 in IR
signaling. However, pharmacological treatment did not affect total IR protein
levels in cancer cells, as it did in adipocytes, indicating some form of cellular
specificity. These data elegantly extend the findings of Kitamura and colleagues.
In their study, they found overexpression of human IR in db/db mice restores
blood glucose levels and improves the obesity phenotype (229). Thus, PGRMC1directed therapeutics have the potential to provide an important approach in
restoring IR function in obese individuals.

6.3 Limitations
This dissertation suffers from the universal limitations surrounding in vitro
model systems. Due to ethical and practical concerns associated with human
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experimentation, initial research is often conducted in animal model systems to
examine preliminary efficacy, toxicity and pharmacokinetics. Indeed, human
cancer cell lines and rodent model systems have driven critical advancements in
understanding the mechanisms associated with disease states. However, the
success rate of clinical translation is limited; the average rate of successful
translation from animal model to clinical cancer trials is less than 8% (230).
The biological differences between human and rodent models was elegantly
demonstrated in our studies using adipocytes. The PGRMC1 ligand, AG205,
increased insulin receptor levels in human samples, but decreased insulin
receptor levels seen in rodent samples. Nevertheless, the FDA requires animal
testing before any human is exposed to new molecular entities (230).
The complexity of the insulin signaling pathway also places limitations on
the scope of this dissertation. The insulin receptor utilizes several substrates to
facilitate multiple functions that include metabolism, growth and aging (210).
Furthermore, insulin signaling varies amongst tissue type and cellular state. In
two cancer cell lines, AG205 treatment affected glucose uptake and insulin
binding, but had no effect on total IR protein levels, an effect seen in human
derived adipocytes. It should also be noted that both the radioactive glucose
uptake and insulin binding assays are downstream functions of insulin, and
insulin can also bind to the IGF-1 receptor (IGF-1R). To address these issues,
further experiments are necessary.
PGRMC1 has only one commercially available ligand, AG205, which has
been used extensively in our research. However, recent studies challenge the
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identification of PGRMC1 to be synonymous to the sigma-2 receptor (S2R) (82,
217). The sigma-2 receptor is a protein associated with tumor cell proliferation
and binds to multiple ligands, including PB28, siramesine and haloperidol (82,
160). The structure of S2R is not known, and the gene remains to be cloned
(82). We have discussed the studies in greater detail surrounding the
identification of PGRMC1 as S2R in earlier chapters. The possibility that
PGRMC1 is indeed the S2R would expand the pharmacological library for
PGRMC1, making it an even more attractive therapeutic. However, until the field
comes to a definitive consensus, there will be limitations on the use of ligand
terms.

6.4 Future directions
This dissertation has provided novel evidence for the role of PGRMC1 in
cancer stem cells, adipose metabolism and the regulation of two receptor
tyrosine kinases, EGFR and IR. Despite advances in research, treatments and
education, cancer and obesity remain worldwide epidemics. Multiple studies
have established obesity as a predominant risk factor for numerous health
conditions, including cardiovascular disease, type 2 diabetes and cancer. It is
our hope that the work presented here will encourage future research into the
biology of such disease states. Perhaps the greatest unanswered questions
involve: (1) IR endocytosis and trafficking, (2) IR isoforms, IGF-1R and
specificity and (3) glucose regulation and (4) the potential interactions between
IR and EGFR.
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6.4.1 IR endocytosis and trafficking
Ligand-dependent endocytosis and sorting for degradation of receptortyrosine kinases (RTKs) are critical steps in modulating the duration and intensity
of receptor function (177). Many studies have investigated the pathways
involved in EGFR trafficking, but very little is known about the endocytosis of IR.
Similar to other RTKs, ligand stimulation at the cell surface promotes receptor
internalization (177). IR endocytosis has been proposed to occur through both
clathrin-dependent and caveolae-mediated pathways, with the latter experiments
performed in primary adipocytes (177). In clathrin-mediated endocytosis, clathrin
relies on adapter proteins to be recruited to the plasma membrane because
clathrin does not bind directly to the plasma membrane or cargo receptors (231).
Following endocytosis, complexes merge with early endosomes and either
become recycled or proceed to the lysosome for degradation (231).
In a previous experiment performed by our lab, density gradient
centrifugation divulged the co-localization of the PGRMC1-EGFR complex to
intracellular microsomes (23). PGRMC1 was found in fractions associated with
the endoplasmic reticulum (calnexin) and secretory vesicles (Rab5), which
increases the likelihood for the PGRMC1-IR co-localization to occur in such (23).
Numerous studies have proposed PGRMC1 to act as an adaptor protein, based
on its modulation of cell surface expression of EGFR, mPRα and ERβ (23, 26).
Taken together, these data would suggest PGRMC1 to associate with IR and
internalize via clathrin-mediated endocytosis. Additionally, PGRMC1 may initiate
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recycling of the PGRMC1-IR complex, because in the absence of PGRMC1,
there are lower levels of IR at the plasma membrane.
Alternatively, PGRMC1 may inhibit the endocytosis of IR, which may
explain why insulin binding was greater in control cells compared to PGRMC1knockdown cells. Furthermore, clathrin-mediated endocytosis may be specific to
cancer cells, as studies reported IR to become endocytosed via caveolae in
adipose (177). Such data further demonstrate the complexity involved in insulin
receptor function and signaling and require additional experiments to dissect the
details.

6.4.2 IR isoforms, IGF-1R and specificity
This dissertation has demonstrated an interaction between PGRMC1 and
IR and identified a role for PGRMC1 in insulin binding. However, it should be
noted that insulin can also bind to another receptor, the IGF-1 receptor (IGF-1R),
and the insulin receptor itself consists of two isoforms. The insulin receptor is
composed of an extracellular α subunit and a transmembrane-spanning β subunit
that are linked via disulfide bonds, and extracellular α subunits bind ligand (210).
Alternative splicing at exon 11 encodes two isoforms of the receptor, isoform A
and B, with the latter isoform containing 12 additional amino acids that are
absent from the extracellular domain of IR-A (210). Insulin-sensitive tissues
predominantly express the IR-B isoform, while IR-A is predominantly found in
cancer cells and is expressed in the brain (164).
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The IR isoforms can therefore provide specificity for pharmacological
targets. Future research will need to identify the IR isoform in specific cell types
and experimental models in order to provide specificity without impairing the total
metabolic effect of insulin. In our data, drug treatment with a PGRMC1 ligand
altered total IR protein levels in human-derived adipocytes, and not cancer cells.
This is a significant finding because the highest expression of IR is found in
adipocytes, and individuals possessing excess adipose have a greater risk for
impaired insulin signaling (210).
Furthermore, intracellular targets may also play a role. The transcription
factor SREBP-1c (sterol regulatory element–binding protein-1c) may play a
critical role in the actions of insulin to regulate adipocyte gene expression, and
PGRMC1 forms a PGRMC1/Insig/Scap/SREBP complex to regulate fatty acid
lipogenesis and cholesterol synthesis (227). PGRMC1 may be working on a
transcriptional level to alter IR levels and mediate adipocyte metabolism through
the cholesterol/steroid pathway.
We also demonstrate a role for PGRMC1 to maintain IR levels at the
plasma membrane in cancer cells. As mentioned earlier, the IR-A form is
predominantly expressed in cancer cells and the brain, and future research
should investigate the PGRMC1-IR interaction and mechanisms in both
physiological settings. Indeed, insulin in the brain has been found to contribute
to the control of nutrient homeostasis, cognition, memory and neuroprotective
effects (232). Alterations in brain insulin metabolism have been suggested as a
pathophysiological factor in neurodegenerative disorders, and Alzheimer’s
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disease patients show a reduction in insulin receptor sensitivity and attenuated
IR expression (233). Our lab is collaborating with the Thibault lab at the
University of Kentucky to investigate the role of IR in cognition. The Thibault lab
specializes in behavioral, electrophysiological, and calcium and glucose imaging
to detect alternations in neuronal functions. Future research will investigate the
role of PGRMC1 in insulin signaling.
IR and IGF-1R are both protein tyrosine kinases that belong to the IGF
system that share a high degree of homology despite being products of two
distinct genes (164). Because of the high degree of homology, the two receptors
can heterodimerize to form hybrid receptors (164). Numerous studies have
investigated the IGF axis in cancer, with an emphasis on IGF-1R and its
involvement in cancer growth and transformation (223). Preliminary studies in
our lab reveal PGRMC1 to regulate IGF-1R in an opposite manner from IR. We
performed a membrane biotinylation experiment in A549 control and A549
PGRMC1-knockdown cells and found IGF-1R plasma membrane levels to
increase in A549 PGRMC1-knockdown cells. IGF-1R is also overexpressed in
cancer, and many clinical trials have investigated anti-IGF-1R blocking
antibodies. IGF-1R blockade has shown only a moderate response in the clinic
(223). Additionally, cells can develop resistance to IGF-1R inhibitors, and IGF1R blockade results in enhanced IR-A homodimer formation and increases IRmediated activity (223). In a study performed by Novosiadly and colleagues,
expression of total IR levels inversely correlated with cixutumumab, a humanized
monoclonal antibody against IGF-1R, efficacy in pediatric solid tumor models in
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vivo (forest et al). Future research is therefore necessary to differentiate the
mechanisms affected by PGRMC1 in both IR and IGF-1R mediated pathways.

6.4.3 Glucose regulation
Glucose homeostasis is coordinated through insulin release from the
pancreatic islet beta cell in response to elevated blood glucose levels, and
peripheral insulin responsive tissues to clear the excess glucose (210). Insulin
binding to the IR initiates the mobilization of glucose transporters from
intracellular vesicles to the plasma membrane. Insulin increases glucose uptake
mainly through enriching concentrations of glucose transporters at the plasma
membrane, and the rate of glucose transport into cells is thus governed by the
concentration of glucose transporters at the cell surface and the duration for
which the protein is remained there (199). The trafficking pathways of vesicles
containing glucose transporters remain unclear, an area in which PGRMC1 is
associated with.
Our data show PGRMC1 to be dependent for glucose transporters, GLUT4 and GLUT-1, expression at the cell surface. Glucose transporter type 4
(GLUT-4) plays a central role in controlling whole body glucose homeostasis and
glucose transporter type 1 (GLUT-1) is frequently upregulated during
oncogenesis (234). We did not investigate the direct interaction between
PGRMC1 and the glucose transporters, therefore future experiments will be
carried out to answer the proposed hypothesis.
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This dissertation also shows glucose uptake to be dependent upon
PGRMC1. As previously mentioned, the concentration of glucose transporters at
the cell surface directly affects the amount of glucose transport into the cell.
Therefore it is possible that glucose uptake is dependent upon PGRMC1
maintaining glucose transporter levels at the plasma membrane. However,
whether this function is dependent on IR signaling or PGRMC1 affecting the
glucose transporter trafficking remains unclear. IR can signal through the
phosphatidylinositol 3-kinase (PI3K) pathway, which is an essential mediator in
glucose uptake (210). Inhibition of the PI3K enzyme completely blocks the
stimulation of glucose uptake by insulin, introducing another area in which
PGRMC1 can modulate the glucose uptake process (199). Furthermore,
PGRMC1 associates with the glucagon-like peptide-1 receptor (GLP-1R) to
enhance GLP-1 induced insulin secretion by modulating the EGFR-PI3K pathway
to potentiate insulin exocytosis (49). We will discuss the potential cross talk
between IR and EGFR in the next section. Future research on the signaling
cascades involved in glucose uptake is necessary to determine the exact role
PGRMC1 plays in the process.

6.4.4 The potential interaction between IR and EGFR
Our lab has established a role for PGRMC1 in regulating both EGFR and
IR at the plasma membrane. Both proteins are intricately involved in a network
of pathophysiological functions across numerous tissue types and disease
states. Understanding the crosstalk between signaling molecules is fundamental
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for designing molecular targeted therapeutics. The EGFR signaling pathway is
one of the best understood receptor signaling pathways and have been used as
main targets in cancer therapy. However, some cancers have been resistant to
EGFR inhibition, suggesting a crosstalk between EGF and other pro-survival
pathways (235).
Both EGFR and IR signal through the PI3K pathway, promote cellular
growth and are involved in tumorigenesis. Furthermore, Capala and colleagues
performed computational and experimental analyses investigating the crosstalk
between EGF, IGF and insulin cell signaling pathways and found Erk1/2, Ak11,
Jnk and p70S6k to be important for crosstalk (235). PGRMC1 has been shown
to directly bind to the G-protein coupled receptor, GLP-1R (glucagon-like peptide1 receptor), and initiate EGFR signaling in pancreatic β cells (23, 47). Several
studies have shown crosstalk between G-protein coupled receptors and IR, and
IR signaling is critical for the protective effect GLP-1 has on pancreatic β cell
function and survival (236).
We have shown that PGRMC1 inhibition in A549 cells causes a reduction
in both EGFR and IR plasma membrane levels. We have not investigated
whether knockdown of PGRMC1 produces a similar cytoplasmic buildup of IR, as
was shown with EGFR. We cannot exclude the possibility that EGFR signaling
affects insulin binding and glucose uptake in the A549 cell line. Activation of
EGFR has been reported to transiently increase glucose uptake, and is a
stabilizer of an active glucose transporter, SGLT1 (200). Future studies should
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carefully consider the role of PGRMC1 in modulating both EGFR and IR, and
develop ways to target each accordingly.
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